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IRF3 is a Critical Regulator of Adipose Glucose and Energy Homeostasis 
Abstract 
 
Obesity is associated with a state of chronic inflammation, which is believed to 
contribute to insulin resistance. We previously identified interferon regulatory factor 3 
(IRF3) as an anti-adipogenic transcription factor with high expression in adipocytes.  
Because IRF3 is known to drive expression of pro-inflammatory genes in immune cells, 
we hypothesized that it may also promote inflammation and insulin resistance in 
adipocytes.  Consistent with our expectations, we found that the expression of 
inflammatory genes in adipocytes was induced by IRF3 overexpression, while 
knockdown of IRF3 had the opposite effect.  Despite this effect on local adipocyte gene 
expression, we found that Irf3
-/- 
mice did not show evidence of altered systemic 
inflammation.  Nonetheless, Irf3-/- mice did display altered metabolism relative to their 
wild type (WT) littermates.  For example, high fat diet (HFD) fed Irf3
-/- 
mice exhibited 
increased lean mass and decreased fat mass compared to WT, accompanied by 
increased food intake and energy expenditure.  Further investigation showed that the 
white adipose tissue (WAT) of Irf3
-/- 
mice had increased expression of brown adipocyte 
selective genes compared to WT, and the inguinal WAT of the Irf3
-/- 
mouse contain 
multilocular adipocytes that resemble brown adipocytes.  These data suggest that IRF3 
affects energy homeostasis by regulating the development of brown adipocyte-like cells 
iv 
 
in WAT.  Additionally, Irf3-/- mice are significantly more insulin sensitive and glucose 
tolerant compared to WT when kept on HFD.  Consistent with in vivo observations, IRF3 
knockdown in 3T3-L1 adipocytes resulted in enhanced insulin-stimulated glucose uptake 
and lipogenesis, while overexpression of constitutively active IRF3 had the opposite 
effect.  Several IRF3 target genes in adipocytes were identified using transcriptional 
profiling.  Interestingly, the expression level of Slc2a4 (encoding the Glut4 protein) was 
inversely correlated with that of IRF3 in both WAT and cultured adipocytes. Analysis of 
the Slc2a4 proximal promoter identified a putative IRF3 binding site upstream of the 
transcription start site, and luciferase assay in 3T3-L1 adipocytes showed that IRF3 
negatively regulates Slc2a4 expression via this site.  Taken together, these data indicate 
that IRF3 plays a role in whole body glucose homeostasis by repressing thermogenic 
gene expression as well as the expression of adipose Glut4. 
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Chapter 1  
Introduction 
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Adipose tissue is an important metabolic organ 
 Adipose tissue was traditionally viewed as an inert tissue that merely provides a 
storage site for triglycerides.  However, over the past twenty years, numerous studies 
have shown that adipose tissue is also an important endocrine organ that produces 
numerous hormones and cytokines that control metabolism, blood pressure, 
hemostasis, and immune responses throughout the body
1
.  Leptin is an adipokine, a 
name referring to cytokines produced by the adipose tissue, which regulates food intake 
by binding specific neurons in the hypothalamus to decrease appetite and stimulate 
energy expenditure
2, 3
.  Adiponectin, another major adipokine, acts on the liver and 
muscle to promote fatty acid oxidation and enhance insulin sensitivity.  Adipose tissue 
also releases inflammatory cytokines such as TNFα and IL-6 that regulate and participate 
in inflammation
4
.  Proteins of the renin-angiotensin system are released by the adipose 
tissue in response to changes in nutritional availability and can act on the vasculature to 
regulate blood pressure and fluid balance
5
.  In addition to initiating efferent signals, 
adipose tissue can also respond to signals from the central nervous system and other 
peripheral organs via various receptors expressed by adipocytes.  For instance, insulin 
secreted by pancreatic β-cells can act on the adipose tissue to stimulate glucose uptake 
during feeding, while glucagon secreted by pancreatic α-cells stimulate the adipose 
tissue to breakdown lipid storage and release fatty acids into the circulation during 
starvation6, 7.  Thus, adipose tissue is an integral part of the metabolic regulatory 
machinery. 
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White vs. brown adipose tissue 
 Two distinct types of adipose tissue exist in mammals, i.e. white and brown 
adipose tissues. They have in common the ability to store lipid in the form of triglyceride; 
however, they are distinct both histologically and functionally, and they have different 
developmental origins
6
.  The predominant form is the white adipose tissue (WAT), 
whose major constituents are white adipocytes, preadipocytes, endothelial cells, and 
immune cells.  WAT is localized in many depots throughout the body, but is often 
characterized as belonging to one of two categories
8
.  Subcutaneous fat can be found in 
relatively small depots under the skin, while visceral fat is located in large intra-
abdominal depots
8
.  Each WAT depot also serves distinct functions, with the intra-
abdominal depots more closely associated with the onset of obesity, diabetes and 
cardiovascular diseases
9, 10
.  Because of its primary function of energy storage and 
mobilization, WAT has the ability to greatly expand in size even in adulthood, surpassing 
any other tissue in the body in this regard
11
.  White adipocytes are characterized by 
large unilocular lipid droplets occupying most of the cytoplasm, squeezing the nucleus 
into a thin rim at the plasma membrane
8
.  
In contrast, brown adipose tissue (BAT) specializes in energy expenditure
7
.  
Compared to WAT, BAT exists in much smaller depots and can be found in interscapular 
depots in mice and supraclavicularly in adult humans
12
.  BAT is mostly made up of 
brown adipocytes, which are characterized by multilocular lipid droplets and abundant 
mitochondria in the cytoplasm, facilitating rapid fatty acid oxidation and heat 
production8.  Compared to WAT, BAT is much better vascularized and innervated8. The 
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major function of BAT is to regulate energy expenditure via adaptive thermogenesis, a 
process unique to this tissue
7
.   
Adaptive thermogenesis is achieved through the function of uncoupling protein 
1 (Ucp1), which is highly expressed in brown adipocytes and localizes to the inner 
mitochondrial membrane7.  In most cell types, the mitochondrial electron transport 
chain establishes an electrochemical gradient across the inner mitochondrial membrane 
and ATP is synthesized as the protons rush back across the membrane13.  In brown 
adipocytes, Ucp1 promotes thermogenesis by allowing dissipation of the mitochondrial 
proton gradient without concomitant ATP synthesis14. Thus, in brown adipocytes oxygen 
consumption results in heat generation instead of ATP production.  Mice lacking Ucp1 
protein are unable to maintain normal body temperature when exposed to a cold 
challenge; they are also susceptible to obesity when maintained under 
thermoneutrality12.  Traditionally, it was thought that in humans BAT only exists in 
infants and disappears with age; however, recent clinical studies have identified active 
BAT depots in the interscapular region of adult human subjects15-18.  Thus, BAT is a 
potential therapeutic target in the treatment of the metabolic syndrome by increasing 
energy dissipation via adaptive thermogenesis, and exploring methods to stimulate the 
generation and activation of BAT may result in new therapeutic approaches. 
 
Adipocyte plasticity 
 Adipocytes are derived from a mesenchymal stem cell lineage
8
.  It was previously 
believed that white and brown adipocytes originate from a common progenitor.  Under 
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the appropriate stimulation, brown adipocytes can arise within WAT and vice versa19.  
For instance, ageing leads to replacement of BAT depots by WAT in both human and 
mice20, 21.  High fat diet-induced obesity leads to morphological changes in BAT that 
leads to the appearance of white adipocyte-like cells
22
.  Conversely, under 
thermogenically challenging conditions, such as chronic cold exposure or 
pharmacological treatment with β3 adrenergic receptor agonists, brown adipocyte-like 
cells, also called “beige” or “BRITE” cells, can be found in WAT depots8, 23.  These beige 
cells histologically resemble brown adipocytes in that they have multilocular lipid 
droplets.  Functionally, beige cells also express Ucp1 and perform adaptive 
thermogenesis
19
. 
 Recent work suggests that WAT and BAT are actually derived from distinct 
precursor populations.  Brown adipocytes were found to be developmentally closer to 
skeletal muscle than white adipocytes24-26.  Brown adipocytes are derived from 
dermatomyotomal precursor cells that express Myf5, which was previously thought to 
be exclusively expressed in committed skeletal muscle precursors24-26.  These precursor 
cells differentiated into brown adipocytes upon induction of the PRDM16 transcription 
factor and turned into muscle cells if PRDM16 is absent.  In contrast, these cells were 
unable to form white adipocytes even when treated with a pro-adipogenic cocktail
24-28
.  
Gene expression analysis also showed that brown adipocyte precursors and skeletal 
muscle cell precursors but not white adipocyte precursors express a closely related gene 
profile
29
.  Lastly, proteomic analysis showed that BAT and skeletal muscle, but not WAT, 
have a highly related mitochondrial proteomic signature
30
. 
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Although it is now clear that WAT and BAT are derived from distinct lineages, 
whether the beige cells appearing in WAT are derived from a BAT or WAT lineage is still 
under debate.  Although these cells appear like brown adipocytes both histologically and 
functionally, they are not derived from a Myf5 positive lineage
25, 26, 28
.  Recent data point 
to the possibility that they are derived from resident mesenchymal stem cells from the 
white adipocyte lineage but poised for “browning”. 
 
Transcriptional regulation of adipogenesis 
 Under conditions of excess nutrition, adipose tissue can generate more 
adipocytes for energy storage by inducing adipogenesis of resident mesenchymal stem 
cells, which have been primed to differentiate into adipocytes7.  Adipogenesis is a 
complex but tightly controlled process that involves the interaction of numerous 
transcription factors.  CCAAT/enhancer binding proteins C/EBPβ and C/EBPδ are two of 
the first major transcription factors to be turned on during adipogenesis.  While their 
induction is early but transient, another family member, C/EBPα, is induced later during 
adipogenesis but remains highly expressed throughout the differentiation process as 
well as in mature adipocytes31.  C/EBPβ, δ, and α in turn induces expression of 
peroxisome proliferator activated receptor γ (PPARγ).  PPARγ is considered to be the 
master regulator of adipogenesis as it is both necessary and sufficient for differentiation 
to occur
32, 33
.  PPARγ forms a heterodimer with retinoid X receptor α (Rxrα), which in 
turn activates transcription of downstream adipogenic genes34, 35.  One of PPARγ’s 
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transcriptional targets is C/EBPα, therefore these two transcription factors form a 
positive feedback loop, allowing both to maintain a high level of expression during the 
adipogenic process and throughout the life of the mature adipocyte33, 36-38. 
 Both PPARγ and C/EBPα turn on the expression of additional transcription 
factors important for adipogenesis as well as mature adipocyte function.  For instance, 
in adipose tissue PPARγ turns on the expression of Pepck, Fabp4, CD36, and lipoprotein 
lipase (Lpl)39, 40.  Similarly, C/EBPα can enhance the expression of Pepck and Fabp4 as 
well as Scd1 and Slc2a4
41-43
. 
 Although PPARγ and C/EBPα are the two major transcription factors regulating 
adipogenesis, this complex process requires the interaction of many other transcription 
factors, both pro-adipogenic and anti-adipogenic.  One prominent pro-adipogenic 
transcription factor is kruppel like factor 15 (Klf15).  It is up-regulated during 
adipogenesis and has been found to induce the expression of PPARγ and Glut444, 45.  
Sterol regulatory element binding protein 1 (Srebp1) has also been found to induce 
PPARγ expression, as well as regulate fatty acid metabolism and cholesterol 
homeostasis
36
.  In contrast, Gata2 and Gata3 negatively regulate adipogenesis by 
transcriptionally down-regulating PPARγ; expression of Gata factors also decreased 
during adipogenesis
38, 46
. 
 
Unbiased search for transcription factors regulating adipogenesis 
 Although many major nodes in the complex adipogenic transcriptional cascade 
have been described, many relevant factors have yet to be identified
38
.  To further 
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understand adipogenesis our lab set out to find additional transcription factors 
regulating this process.  One way to predict transcription factor involvement in 
biological processes is to analyze chromatin structure changes throughout the process47.  
Thus we employed DNase hypersensitivity assay followed by computational motif 
finding to identify transcription factors involved in adipogenesis.   
The DNase hypersensitivity assay takes advantage of the ability of small amounts 
of DNase I to digest regions of open chromatin while leaving compact heterochromatin 
intact
47, 48
.  Open chromatin is known to be associated with promoters, enhancers, 
silencers, insulators, and other regions with active transcription factor binding47-49.  
Because we were specifically interested in adipogenesis we focused on studying the 
changes in chromatin state in 3T3-L1 preadipocytes and adipocytes.  To find chromatin 
regions active during adipogenesis, we reviewed relevant literature to identify 27 key 
genes that showed relatively adipocyte-specific expression and whose expression levels 
were induced during adipogenesis.  These 27 genes are all well known players in 
adipogenesis, e.g. Pparγ, Cebpα, Fabp4, etc.  We restricted our search to highly 
conserved regions within 50kb upstream and in the first intron of the 27 selected genes 
and designed primers specific for each of the identified regions.  Q-RTPCR on DNase I 
digested chromatin from 3T3-L1 preadipocytes and adipocytes identified 32 regions that 
had reduced copy numbers in DNase I digested adipocyte chromatin compared to 
preadipocyte chromatin, or in other words, were DNase I hypersensitive
50
.  
Computational motif finding was employed to identify overrepresented motifs in these 
32 regions
50-52
.   
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From this assay, we identified the orphan nuclear receptor chicken ovalbumin 
upstream promoter transcription factor II (COUP-TFII) as a regulator of adipogenesis
53
.  
We performed in vitro assays using 3T3-L1 preadipocytes to confirm this finding.  
Overexpression of COUP-TFII in 3T3-L1 preadipocytes suppressed adipogenesis, while 
knockdown enhanced adipogenesis53.  These results indicate that the combination of 
DNase hypersensitivity assay and computational motif finding is a valid approach to 
identify novel transcription factors in adipogenesis.  In addition to COUP-TFII, one of the 
top scoring motifs identified was a binding site for interferon regulatory factors (IRFs), 
known as interferon stimulated regulatory element (ISRE)50. 
 
IRFs 
IRFs are a family of transcription factors that play a variety of critical roles in the 
immune system.  There are nine members in the mammalian IRF family, IRF1 through 
IRF9, each serving distinct roles in host defense, growth control, and 
immunomodulation
54
.  All nine IRFs contain a well conserved helix-turn-helix DNA 
binding domain (DBD) in their N-terminus, which binds the ISRE in the promoter region 
of target genes
55
.  The C-terminus domain of IRFs consists of an IRF association domain 
(IAD), mediating interactions with other IRFs and additional transcriptional co-
modulators, as well as clusters of phosphorylation sites conferring post-translational 
regulation.  This region is distinct for each IRF family member55 (Figure 1.1). 
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Figure 1.１The interferon regulatory factor protein family. 
The structure of the nine proteins in the mammalian IRF family.  All IRFs contain a well-
conserved DNA binding domain (DBD, blue) defined by five tryptophan residues (W).  
The regulatory domain (green) is in the C-terminus.  Most IRFs also contain either IRF 
association domain type 1 (IAD1) or type 2 (IAD2).  Some members of the IRF family also 
contain repression domains (yellow) or nuclear-localization signals (orange).  Some IRFs 
are regulated by phosphorylation (P) in their regulatory domains.  Figure adapted from 
Lohoff and Mak, Nature Reviews Immunology 200555. 
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IRFs were originally named for their ability to induce type I interferons upon 
infection
56
; however, further studies revealed IRFs to be involved in a diverse group of 
immune functions.  They are important players in the regulation of innate immune 
response, cell growth, apoptosis, and oncogenesis, and the development and 
maturation of various immune cells including dendritic cells, myeloid cells, natural killer 
cells, B cells, T cells, and erythroid cells
54, 55, 57
.  
Although IRFs are very well studied in the context of immunity, there have been 
no previous reports of their function in adipocytes.  We found all nine IRFs to be 
expressed in 3T3-L1 adipocytes, in a developmentally-regulated fashion, as well as in the 
adipose tissue of mice (Figure 1.2)
50
.  Additionally we performed a combination of ChIP, 
EMSA, and luciferase assays in 3T3-L1 preadipocytes versus adipocytes.  These results 
confirmed the adipocyte specific binding of several IRFs to the ISRE sites predicted by 
the DNase I hypersensitivity assay50. 
Gene expression analysis in 3T3-L1 adipocytes showed that all nine IRFs are 
expressed in adipocytes.  However, IRF3 and IRF4 were particularly interesting in that 
they exhibited low expression levels in preadipocytes and were significantly induced in 
the mature adipocyte (Figure 1.2A)50, indicating that in addition to adipogenesis they 
may also play an important role in mature adipocyte function.    
12 
 
   
Figure 1.２IRFs are expressed in adipocytes. 
A) Expression of all nine IRFs during 3T3-L1 differentiation as determined by Q-RTPCR.  
The shaded area indicates time points <24hr after induction of adipogenesis, n=3.  B) 
IRF3 expression in tissues from male FVB mice as determined by Q-RTPCR.  Br: brain, H: 
heart, Lu: lung, Liv: liver, K: kidney, Sp: spleen, Int: intestine, WAT: epididymal white 
adipose tissue, BAT: interscapular brown adipose tissue, n=3.  C) IRF3 expression in the 
fractionated epididymal fat pads of C57BL/6 mice.  SVF: stromal vascular fraction, Macs: 
F4/80 positive macrophages, Ads: adipocytes, n=6, **P < 0.01 versus SVF, n.d. = not 
detectable.  Figure adapted from Eguchi et al. Cell Metabolism 2008
50
. 
 
We studied the role of IRF4 in adipocytes by characterizing the metabolic 
phenotype of mice lacking IRF4 in adipocytes.  These mice exhibit increased adiposity 
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and deficient lipolysis58.  Mechanistic studies showed IRF4 to be a critical determinant of 
the transcriptional response to nutrient availability in adipocytes.  Fasting induces IRF4 
in an insulin- and FoxO1-dependent manner, and IRF4 is required for lipolysis, at least in 
part due to direct effects on the expression of adipocyte triglyceride lipase (ATGL) and 
hormone-sensitive lipase (HSL) (Figure 1.3)58.   
 
Figure 1.３IRF4 is a transcriptional regulator of adipose nutrient response. 
 
In addition to IRF4, IRF3 expression is also upregulated in the mature 3T3-L1 
adipocytes (Figure 1.2A)
50
.  We found IRF3 to be expressed in all tissues tested, including 
WAT and BAT (Figure 1.2B).  When the epididymal WAT was fractionated, the 
expression level of IRF3 was higher in the adipocytes compared to the infiltrating 
macrophages, as well as the stromal vascular fraction (SVF) (Figure 1.2C)
50
. 
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IRF3 was also found to be an important player in adipogenesis.  In 3T3-L1 
preadipocytes over-expressing IRF3, adipogenesis was greatly attenuated as measured 
by both Oil-Red-O staining of triglyceride content (Figure 1.4A) and gene expression 
analysis of key markers of adipogenesis such as Pparγ, Cebpα, Fabp4, etc. (Figure 1.4B).  
Conversely, shRNA-mediated IRF3 knockdown in 3T3-L1 adipocytes resulted in 
enhanced adipogenesis (Figure 1.4C and D)
50
.  These data indicate IRF3 to be a 
transcription factor regulating both adipogenesis and adipocyte function. 
15 
 
 
Figure 1.４IRF3 is anti-adipogenic in 3T3-L1 cells. 
A - B) 3T3-L1 preadipocytes were transduced with retrovirus expressing IRF3, then 
differentiated with a dexamethasone, IBMX, and insulin cocktail (DMI).  Experiments 
were performed seven days post-differentiation.  A) Oil-Red-O staining.  B) Q-RTPCR of 
adipocyte selective genes.  C - D) 3T3-L1 preadipocytes were transduced with lentivirus 
A B
C D
Overexpression
Knockdown
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Figure 1.4 (Continued). expressing shIRF3 and differentiated with DMI.  C) Oil-Red-O 
staining was performed at three, five, and seven days post differentiation.  D) Q-RTPCR 
of adipocyte selective genes was performed seven days after differentiation.  *P<0.05, 
**P<0.01, n=3.  Figure adapted from Eguchi et al. Cell Metabolism 2008
50
. 
 
IRF3 
Although its role in metabolism has not been characterized, IRF3 has been well 
studied in the context of immunity.  It is recognized as the major effector of the 
induction of interferon gene expression as part of the innate immune response to viral 
infection59-61.  Additionally, IRF3 has also been implicated in viral as well as bacterial 
mediated apoptosis
57
. 
IRF3 is a unique member of the IRF family in that it is constitutively expressed in 
all cells and tissues, while its activity in innate immune response is regulated post-
translationally61.  There are two clusters of phosphorylation sites in the C-terminus 
region of IRF3.  The first region is located at Ser385/Ser386, while the second region is at 
Ser396/Ser398/Ser402/Thr404/Ser40562, 63.  Upon viral infection, IRF3 is phosphorylated 
at its C-terminus.  Although the precise residue critical for IRF3 activation is still a 
subject of intense debate64-67, it is widely accepted that phosphorylation must occur 
within the 385-405 amino acid region for IRF3 to be activated
68-70
, and mutation of the 
serine residues in this region into aspartic acid results in a constitutively active IRF3 
mutant
69
 (Figure 1.5).  Phosphorylated IRF3 undergoes a conformational change that 
exposes the DBD and the IAD, facilitating homo-dimerization as well as interaction with 
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the CREB/p300 cofactor62, 63, 71.  Binding with CREB/p300 allows IRF3 to shuttle into the 
nucleus where it forms a complex with other viral response proteins such as NF-κB
72-
75.  This complex can then bind to ISRE sequences and induce transcription of genes 
critical for the antiviral response, including Ccl5, Ifnβ, and Ifit1
59, 61, 76, 77
.  Activated IRF3 
is shuttled out of the nucleus via its nuclear export sequence, after which it rapidly 
undergoes proteasomal degradation, thus ensuring the timely termination of the 
inflammatory response70, 75, 78, 79. 
 
Figure 1.５Schematic of the IRF3 protein. 
The IRF3 protein has a cluster of phosphorylation sites in its C-terminus.  Mutation of 
amino acids 396 and 398 from serine to aspartic acid results in the 2D mutant that is 
constitutively active. 
 
           The signaling pathways leading to IRF3 activation in the adipocyte have not been 
identified, but it is well studied in immune cells.  IRF3 activation is initiated by pathogen 
associated molecular patterns binding to toll like receptor 4 (TLR4), located on the cell 
surface
54, 61
.  TLR4 recognizes a diverse group of ligands including lipopolysaccharide 
(LPS), the fusion protein of respiratory syncytial virus, and certain free fatty acids 
(FFAs)
80-82
, while its signaling depends on four adaptor molecules, including myeloid 
WT     SNSHPLSLTS
2D      DNDHPLSLTS
P
N C
396 405
IRF3 P
DBD
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differentiation factor 88 (MyD88)83, 84, TIR domain containing adaptor protein (TIRAP)85, 
86
, TIR containing adaptor molecule 1 (TICAM1)
87, 88
, and TRIF related adaptor molecule 
(TRAM)89, 90.  Ligand binding activates two pathways downstream of TLR4: the MyD88-
dependent and the MyD88-independent pathways.  Signaling through the MyD88-
independent pathway activates Iκβ kinase ε (IKKε) and TANK binding kinase 1 (TBK1), 
which together phosphorylate IRF3, leading to its dimerization and translocation
91-93
 
(Figure 1.6). 
 
Figure 1.６IRF3 signaling pathway in immune cells. 
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Interestingly, TLR4 has been implicated in the crosstalk of innate immunity and 
metabolism as well.  TLR4 is expressed in adipocytes and has been shown to be a target 
of free fatty acids, which are present at increased levels during obesity80.  FFAs increase 
the expression of inflammatory cytokines downstream of TLR4, such as IL-6 and TNFα, 
while deletion of TLR4 substantially decreases levels of inflammatory cytokines and 
ameliorates the FFA-mediated insulin resistance
80, 94
.  Hematopoietic cell-specific 
deletion of TLR4 via bone marrow transplantation results in protection from HFD 
induced insulin resistance
94
.  This is exemplified by decreased serum insulin and 
enhanced glucose clearance in the insulin tolerance test.  Hematopoietic cell-specific 
TLR4 deletion also results in improved hepatic insulin resistance and decreased hepatic 
and adipose inflammation on HFD94.  Thus TLR4 in hematopoietic-derived cells is a 
regulator of whole body insulin response. 
IKKε has also been found to play a role in metabolism.  Diet induced obesity 
increases the expression of IKKε in adipose tissue and liver
95
.  IKKε knockout mice are 
protected from diet induced obesity and show increased body temperature, energy 
expenditure, and food intake.  The IKKε mouse also exhibits enhanced insulin sensitivity 
compared to WT when challenged with high fat diet (HFD), with decreased serum 
glucose, insulin, and cholesterol levels, as well as better performance in both the 
glucose tolerance test and the insulin tolerance tests.  Additionally, IKKε knockout mice 
are also protected from HFD induced hepatic steatosis and obesity induced systemic 
inflammation
95
.   
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Because IRF3 is a major downstream transcription factor of both TLR4 and IKKε61, 
91
, it is likely to be involved in the gene regulation events leading to the downstream 
effects of both proteins.  Thus we hypothesize IRF3 to be a player in the transcriptional 
regulations mediating the crosstalk between immunity and metabolism. 
 
Obesity and inflammation are closely linked 
 The actions of the immune system and the metabolic machinery are closely 
linked.  Clinical observations show that obese patients exhibit 2-3 fold elevated 
circulating levels of proinflammatory cytokines including TNFα, IL-6, and C-reactive 
protein (CRP) corresponding to decreased insulin sensitizing hormones, such as 
adiponectin
96-98
.  Obesity is not only associated with chronic low grade systemic 
inflammation, peripheral tissues including adipose tissue, liver, and muscle are also 
found to be in an inflamed state during obesity
99
.  This state of inflammation is a crucial 
contributing factor to the comorbidities of obesity, including insulin resistance and type 
2 diabetes (T2D)
97, 100, 101
.  
 Obesity is characterized by the expansion of the adipose tissue102, 103.  This 
expansion is due to both adipocyte hyperplasia and hypertrophy to accommodate the 
need for storage space for the excess fuel102, 104.  Rapid WAT expansion results in 
hypoxia in poorly vascularized regions of the tissue which eventually become necrotic.  
Macrophages are recruited to the necrotic regions to remove dying adipocytes105, 106.  
Activated macrophages surround the dying cells, forming “crown like structures,” which 
are now recognized as a classic sign of obesity associated inflammation
105-108
. 
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Even though macrophages were the first immune cells discovered to infiltrate 
WAT, recent data have demonstrated that WAT becomes infiltrated by many other 
groups of immune cells, including T cells109, 110, B cells111, mast cells112, and 
eosinophils
113
.  These resident immune cells, as well as the adipocytes themselves, 
contribute to the WAT inflammatory milieu114.   
In obese mouse models, adipocytes and resident immune cells exhibit increased 
expression of inflammatory cytokines including TNFα, IL-6, IL-10, and IL-1β4, 7.  Mouse 
studies have shown TNFα to be a major factor in obesity-associated insulin resistance.  
TNFα protein and mRNA levels are increased in obese humans as well as in mouse 
models of obesity
115-121
.  Expression of TNFα is positively correlated with the level of 
obesity as measured by the body mass index and insulin resistance as assessed by serum 
insulin
118, 119
.  Conversely, TNFα expression is negatively correlated with lipoprotein 
lipase activity in the adipocyte122.  Antibody neutralization of TNFα can lower serum 
glucose levels and improve insulin resistance in obese mice
123-125
.  TNFα deficient mice 
develop diet-induced obesity similar to WT.  Despite a similar degree of obesity, TNFα 
deficient mice are protected from obesity-induced insulin resistance, exhibited by lower 
serum insulin and enhanced glucose clearance in both the glucose and insulin tolerance 
tests
126
.  Alternatively, when the genetically obese model of ob/ob mice are crossed 
with mice harboring a loss-of-function mutation in the p55 and p75 TNFα receptors, the 
resulting animals exhibit decreased serum glucose and insulin, as well as enhanced 
performance in the insulin and glucose tolerance tests compared to ob/ob mice with WT 
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TNFα receptors126.  In vitro, TNFα treatment also hinders insulin stimulated glucose 
uptake in 3T3-L1 adipocytes
117, 127
.   
Functional studies show that TNFα interferes with the metabolic function of the 
adipocyte via multiple pathways.  First, it can increase reactive oxygen species (ROS) in 
adipocytes, which induces insulin resistance128, 129.  TNFα treatment of 3T3-L1 
adipocytes results in the upregulation of ROS-related genes, and the addition of 
antioxidants can prevent 25-65% of the insulin resistance caused by TNFα127.  These 
results indicate that TNFα induces adipose insulin resistance at least in part via elevating 
ROS.  Secondly, it can impair insulin signaling by interfering with insulin receptor 
substrate 1 (IRS1) tyrosine phosphorylation, thus inhibiting subsequent PI-3 kinase (PI-
3k) activation and insulin stimulated glucose uptake117, 130-132.  In addition, it can 
interfere with lipid storage by down-regulating fatty acid transport and lipoprotein 
lipase, resulting in increased lipolysis100, 133.  
 Another inflammatory cytokine, IL-1β, is also a mediator of obesity-induced 
inflammation.  Mice lacking IL-1β or the IL-1β receptor are protected from diet induced 
obesity induced insulin resistance
134, 135
.  Clinically, type 2 diabetic patients also show 
increased IL-1β, while weight loss in type 2 diabetic patients results in reduced adipose 
IL-1β expression
136
.  Mechanistically, IL-1β directly inhibits insulin signaling via negative 
regulation of IRS-1 expression and hindrance of IRS-1 tyrosine phosphorylation, which 
together contribute to insulin resistance
137
.   
IL-1β is a component of the NOD-like receptor family pyrin domain-containing 3 
(NLRP3) inflammasome protein complex, which plays a role in the innate immune 
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response to infection138.  Activation of the NLRP3 inflammasome leads to caspase-1-
dependent cleavage of the latent pro-IL-1β into the active IL-1β
139
.  Studies indicate 
Caspase-1 to also be involved in whole body metabolism.  Metabolic characterization of 
Caspase-1 deficient mice show protection from diet-induced obesity and improved 
insulin sensitivity on HFD140. 
 In addition to TNFα and IL-1β, numerous other cytokines have been implicated in 
obesity associated inflammation97.  For instance, IL-6 expression is increased in both the 
adipocytes and infiltrating immune cells in WAT during obesity, and elevated IL-6 levels 
have been found to promote insulin resistance97. 
 In addition to proinflammatory cytokines such as TNFα and IL-1β, many kinases 
involved in the inflammatory signaling pathway are also activated in obese adipose 
tissue.  This includes the kinase c jun N terminal kinase (JNK)
141
, inhibitor of NF-κB kinase 
(IKKβ)142, 143, and protein kinase C (PKC)144-146.  Previous studies have also implicated 
these signaling molecules in obesity associated insulin resistance.  For instance these 
kinases can activate NF-κB, resulting in further increase in proinflammatory cytokine 
expression
97, 100
.   
Interestingly, the actions of NF-κB are closely related to that of IRF3 in immunity.  
NF-κB is a key player in the innate immune response
147
.  Like IRF3, latent NF-κB is 
sequestered in the cytoplasm.  Signaling through TLR4 leads to activation and nuclear 
translocation of NF-κB
148
.  Nuclear NF-κB can form a heterodimer with IRF3 to activate 
transcription of downstream genes, including inflammatory cytokines such as TNFα and 
IL-6
147, 148
.  Obese patients show chronically increased activation of NF-κB in the adipose 
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tissue149.  Treating mice with glucose or lipid infusions can also increase adipose tissue 
NF-κB activity
142, 146, 150, 151
.  In vitro, palmitate treatment activates NF-κB in cultured 
3T3-L1 adipocytes152.  Conversely, stimulation with adiponectin or PPARγ, which are 
both insulin sensitizers, suppresses NF-κB activity in adipocytes
153-155
. 
JNK, IKKβ, and PKC also directly interfere with insulin signaling by 
serine/threonine phosphorylating IRS1, thus preventing its activation and downstream 
PI-3K recruitment, resulting in the inability to activate the insulin signaling pathway97, 144, 
145
.  Metabolic characterization of JNK1 deficient mice shows that they are protected 
from diet induced obesity and insulin resistance141.  Mice heterozygous for IKKβ exhibit 
enhanced insulin sensitivity
143
.  Clinical studies show that treatment with salicylates, 
which are known IKKβ inhibitors, enhances insulin sensitivity in patients with type 2 
diabetes
97, 100, 133
.   
 The interaction between the metabolic and the immune system has been a field 
of intense study in the past two decades.  It is now well accepted that many signaling 
molecules can both activate inflammatory pathways while inhibiting metabolic function 
and many cytokines can signal to both immune and metabolic organs.  However, the 
transcriptional pathways regulating this crosstalk are still unknown.  We believe that 
studying the role of IRF3 in adipocytes will shed light on this question. 
 
Overview of Dissertation 
 Chapter 2 of this dissertation will discuss the role of IRF3 in promoting the 
inflammatory milieu in both WAT and cultured adipocytes.  We employed lentiviral 
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mediated IRF3 overexpression and knockdown in 3T3-L1 adipocytes followed by gene 
expression analysis to study the effect of IRF3 on the adipocyte inflammatory profile.  
The inflammatory state of WAT in Irf3-/- mice is characterized by studying the extent of 
WAT macrophage infiltration.  Chapter 3 focuses on discovering how IRF3 regulates 
energy homeostasis.  We studied the thermogenic profile of IRF3 whole body knockout 
mice.  The effect of IRF3 on adipocyte “browning” is also characterized using cultured 
primary adipocytes from the SVF of the inguinal WAT of WT vs. Irf3-/- mice.  Chapter 4 
looks into the role of IRF3 on insulin action.  We characterized the metabolic phenotype 
of the Irf3-/- mice.  Additionally we studied the effect of IRF3 on insulin action in cultured 
adipocytes.  In summary we found IRF3 to strongly elevate inflammatory genes in 
adipocytes.  Furthermore, it also influences energy homeostasis by suppressing adipose 
tissue “browning” and regulates glucose homeostasis by transcriptional control of 
adipose Slc2a4.
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Chapter 2  
IRF3 regulates adipocyte inflammation 
27 
 
Introduction 
 
IRFs are transcription regulators of type I interferon and interferon-inducible 
genes
57
.  Specifically, IRF3 is recognized as the major effecter of the induction of 
interferon gene expression as part of the innate immune response to viral infection
61
.  
Upon viral infection, TLRs recognize pathogen-associated molecular patterns, and then 
activate the innate immune response pathway
54
.  IRF3 acts downstream of TLR4, which 
recognizes a diverse group of ligands, including bacterial LPS, the fusion protein of 
respiratory syncytial virus, and FFAs
54, 80
.  Ligand binding to TLR4 causes IRF3 to become 
phosphorylated, after which it dimerizes and translocates into the nucleus, where it 
activates downstream genes including Ccl5, Ifnβ, and Ifit1
69, 91
.  Activation of these 
interferon response genes results in the mounting of the host innate immune 
response
54
.  In addition to activating the innate immune response, IRF3 is a mediator of 
bacteria-induced apoptosis in macrophages, which is triggered upon TLR4 activation
60
.  
Lastly, IRF3 is also a downstream mediator of DNA dependent protein kinase, which 
activates DNA damage induced apoptosis
57
. 
Sato et al. created the Irf3-/- mouse in 2000 and characterized its immunological 
phenotype
156
.  Consistent with IRF3’s role in the innate immune response, the Irf3-/- 
mouse was found to be susceptible to encephalomyocarditis virus infection
156
.  
Additionally, the Irf3-/- mouse was also found to be resistant to LPS-induced endotoxic 
shock, which is expected since IRF3 is a mediator of LPS induced TLR4 signaling
157
.  
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However, no abnormalities were observed in the size, behavior, or reproduction of Irf3-/- 
mice
156
. 
In the past 20 years there has been a growing recognition of the close link 
between the immune system and the metabolic system.  Obesity is associated with 
chronic low grade systemic inflammation, and peripheral metabolic tissues including 
adipose tissue, liver, and muscle also show signs of inflammation during obesity
97
.   
Under obese conditions the adipose tissue quickly expands in order to store the 
excess energy in the form of lipids
102, 103
.  Rapid WAT expansion results in hypoxia in 
poorly vascularized regions of the tissue which eventually becomes necrotic106.  
Macrophages are recruited to the necrotic regions to remove the dying adipocytes
97, 105
.  
Resident macrophages also switch from the M2 polarized anti-inflammatory state 
during lean conditions toward a M1 polarized pro-inflammatory state during obese 
conditions158, 159.  Additionally, obesity also elevates the secretion of inflammatory 
cytokines in the adipose tissue including TNFα, IL-6, IL-10, and IL-1β
4, 7
.   
Interestingly, IRF3 has been implicated in the crosstalk between immune 
response and metabolic function.  Activation of IRF3 during viral infection inhibits liver X 
receptor (LXR) activation and downstream induction of Abca1 in macrophages.  This 
leads to an inability of macrophages to rid themselves of excess cholesterol during an 
infection
160
.  Additionally, statins, which are inhibitors of the HMG-CoA reductase 
enzyme in cholesterol production, have also been found to inhibit IRF3 activation in 
macrophages
161
. 
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One the other hand, IRF3 function in macrophages can also be inhibited by 
nuclear receptor signaling.  Treatment with the Pparγ ligand troglitazone inhibits IFN-β 
production in mice following LPS injection162.  In vitro studies in macrophages found that 
troglitazone prevents IRF3 binding to the ISRE site in the Ifnβ promoter while enhancing 
Pparγ binding to the same site.  This results in a reduction of IFN-β production in 
macrophages during microbial infection
162
.   
Since IRF3 is highly expressed in adipocytes, we hypothesized that IRF3 is also a 
transcriptional regulator of the inflammatory pathway in adipocytes.  We speculated 
that deletion of IRF3 may hamper activation of the inflammatory pathway in adipocytes 
of Irf3-/- mice, and would subsequently lead to reduced overall systemic inflammation 
during the obese state, with beneficial metabolic consequences. 
 
Materials and methods 
 
3T3-L1 adipocytes 
3T3-L1 cells (ATCC) were cultured in high glucose DMEM (Invitrogen) 
supplemented with 10% bovine calf serum (Hyclone).  Proliferating cells were 
maintained at or below 70% confluency.  For adipogenic differentiation, cells were 
grown until two days after confluency then stimulated with an adipogenic cocktail 
including dexamethasone, insulin, and isobutylmethylxanthine in high glucose DMEM 
supplemented with 10% fetal bovine serum (FBS) (Atlas Biologicals)
163, 164
.  Cells were 
stimulated for 48 hours, after which they were maintained on high glucose DMEM/FBS 
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until further experimentation.  All experiments were performed at least seven days after 
adipogenic differentiation to ensure that adipogenesis was complete. 
 
IRF3 knockdown and overexpression in 3T3-L1 adipocytes 
 IRF3 knockdown and overexpression experiments were performed by lentiviral 
transduction into mature 3T3-L1 adipocytes.  For overexpression experiments, IRF3 
cDNA was cloned into the pCDH-CMV-MCS-EF1-puro lentiviral construct (System 
Biosciences).  For knockdown experiments shIRF3 hairpin designed by the Broad 
Institute RNAi Consortium (TRCN0000085242) was cloned into pSIH1-H1-copGFP 
lentiviral construct (System Biosciences). 
 Lentivirus was generated by transient transfection of the appropriate viral 
construct and two packaging vectors pMD2.g and psPAX2 (Addgene) in a mass ratio of 
10μg:5μg:5μg respectively into ~80% confluent HEK293T cells using the ProFection 
calcium phosphate transfection kit (Promega).  Transfected HEK293T cells were changed 
into fresh high glucose DMEM medium (Gibco) containing 10% FBS (Atlas Biologicals) 16 
hours later.  The viral-laden media was collected 48 hours after the transfection, filtered 
through a 0.4uM filter (BD Biosciences), and frozen down at -80⁰C for later use. 
 3T3-L1 adipocytes were transduced with lentivirus 7 days after adipogenic 
differentiation.  Viral-laden media was warmed to room temperature and mixed with 
7ug/ml polybrene then applied to 3T3-L1 adipocytes for 12hr.  To achieve optimal 
transduction efficiency, 3T3-L1 adipocytes were subjected to 2 successive rounds of viral 
transduction.  At the end of a total of 24hr of viral transduction 3T3-L1 adipocytes were 
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switched back to fresh DMEM media containing 10% FBS.  Subsequent experiments 
were performed 6-10 days after viral transduction. 
 
Microarray 
 Microarray was performed using cDNA from 3T3-L1 adipocytes after IRF3 
overexpression or knockdown.  All experiments were performed in duplicates.  Illumina 
mouse whole genome microarray was used for this experiment, and all procedures were 
performed by the Broad Institute genetic analysis platform. 
Normalization:  All data were normalized using the quantile algorithm implemented in 
the 'limma' package in R. All signal intensities were log2 transformed. 
Differentially expressed genes: We first set the cutoff of fold-change as 0.35. There were 
< 0.1% probes with fold-change > 0.35 or < -0.35 in pairs of biological repeats.  We then 
set the cutoff of signal intensity as 6.6. Only < 0.1% probes in background may have 
signal intensity > 6.6 according to Illumina's array image scanning results.  
The differentially expressed genes met the following criteria: 
1. Maximal signal intensity > 6.6 in EGFP, IRF3, shLuc, or shIRF3 samples  
2. Absolute value of fold-change was greater than 0.35 in both IRF3 vs. EGFP comparison 
and shLuc vs. shIRF3 comparison. 
3. The directions of differential expression in EGFP vs. IRF3 comparison and in shLuc vs. 
shIRF3 comparison are the opposite. 
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Pathway analysis: Gene Set Enrichment Analysis (GSEA) algorithm was used to identify 
KEGG pathways significantly associated with the expression profile alteration between 
different conditions. 
Heatmap: All signals in heatmaps were pseudo-relative signals. For the purpose of 
visualization, we artificially normalized signals so that pseudo-signals at each row in 
heatmaps have a mean value of 0 and standard deviation of 1. 
 
Q-PCR 
 Tissue was harvested from mice and homogenized in Trizol (Invitrogen).  Total 
RNA was harvested using the manufacturer’s suggested protocol.  mRNA concentration 
was measured using a NanoDrop ND-1000 spectrophotometer and 1ug of mRNA was 
then used to synthesize cDNA using the RETROscript 2-Step RT-PCR Kit (Ambion).  The 
resulting cDNA product was diluted by 10-fold with water and subjected to real time 
qPCR with the SybrGreen reagent (ABI) in the ABI 7900-HT qPCR apparatus.  36B4 was 
utilized as an internal control for each sample.  Relative expression of each gene was 
calculated using the ΔΔCt method. 
 
Animals 
 All animal procedures used in this study were approved by the Institutional 
Animal Care and Use Committee (IACUC) of Beth Israel Deaconess Medical Center.  All 
mice were kept under 12 hr light : dark conditions at an ambient temperature of 73⁰F 
(22.8⁰C).  Mice were housed at 1-5 per cage and were fed ad libitum on chow diet 
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consisting of Purina Diet #5008.  High fat diet (HFD) fed animals were given Research 
Diets #D12331i with 58% kcal from fat beginning at three weeks of age. 
 The Irf3-/- mice were purchased from Riken BioResource Center.  These mice 
have been completely backcrossed onto a C57BL/6 background, and all subsequent 
generations were maintained on a C57BL/6 background. 
 Mice cohorts were generated by mating heterozygous males and females with 
each other, and offsprings were born in genotypes in the expected Mendelian ratios.  
WT and Irf3
-/-
 littermates were used for all studies. 
 
Serum cytokine measurements 
 Mice were fasted overnight and fasting serum was collected from cheek bleed 
using a 5.5mm sterile animal lancet (Goldenrod).  Fasting serum was separated from 
whole blood by centrifugation at 3000 rpm for 5 min at 4⁰C in BD Microtainer serum 
separator tubes (BD Bioscience #365956).  Serum MCP-1 was measured using the 
Quantikine mouse MCP-1 immunoassay kit (R&D Systems #MJE00).   
 
Tissue histology 
 WAT and BAT were collected from chow and HFD-fed mice.  Fresh tissue was 
fixed by incubating in 4% paraformaldehyde in PBS overnight at 4⁰C.  Fixed tissue was 
paraffin embedded, sectioned, and mounted onto microscope slides.  Slides were 
stained with hematoxylin-eosin (H&E), anti-F4/80, or anti-UCP1 (Abcam #ab10983).  All 
tissue histology was performed by the BIDMC histology core facility. 
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 Tissue slides were visualized using a Zeiss Axio Imager A1 microscope fitted with 
a Zeiss Axiocam at 10 times magnification.   
 
Statistical analysis 
 Unpaired t-tests or one-way ANOVA were applied to the data with either 
Bonferroni or Fisher-post hoc tests. 
 
Results 
 
Lentiviral transduction can effectively manipulate IRF3 expression in 3T3-L1 adipocytes. 
 We sought to study the effects of IRF3 on inflammatory gene expression in 
adipocytes using gain- and loss-of-function models. We began our analysis in 3T3-L1 
cells, one of the best characterized models of adipocytes in culture
165, 166
.  We and 
others have long used retroviral vectors to manipulate gene expression in proliferating 
cell lines such as 3T3-L1 preadipocytes.  However, we have previously identified IRF3 as 
an inhibitor of adipogenesis, and so to study the role of IRF3 in mature adipocytes, all 
manipulations must be performed after differentiation is complete.  Since mature 3T3-
L1 adipocytes are notoriously difficult to transfect with reagents such as calcium 
phosphate or lipofectamine, we chose lentiviral-mediated transduction for this study. 
 The mouse IRF3 cDNA was cloned into the pCDH lentiviral vector for 
overexpression experiments.  Previous studies in immune cells have shown that under 
basal conditions IRF3 resides in the cytoplasm and is inactive.  Under appropriate 
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stimulation, such as during viral infection, IRF3 becomes phosphorylated, undergoes 
dimerization, and subsequently translocates into the nucleus, where it can activate 
transcription of downstream genes61, 91.  A cluster of key phosphorylation sites involved 
in this process has been identified in the C-terminus of the IRF3 protein, and mutation of 
amino acids 396 and 398 from serine to aspartic acid has been found to result in a 
constitutively active form of IRF3 that can translocate into the nucleus and activate 
transcription of downstream genes without additional stimulation62, 63, 69.  Therefore, to 
mimic active IRF3 we mutated amino acids 396 and 398 to create a constitutively active 
pCDH lentiviral IRF3 construct. 
 Overexpression of IRF3 was performed by lentiviral transduction into 3T3-L1 
mature adipocytes seven days after differentiation, which we consider to represent the 
mature state.  An EGFP-expressing viral vector was used as control.  Two days after viral 
transduction, visualization of EGFP shows very high transduction efficiency of ~90% 
(Figure 2.1A).  Six days after viral transduction, RNA and protein were harvested and Q-
RTPCR and Western blot experiments were performed to assess IRF3 overexpression 
efficiency.  Q-RTPCR showed significant overexpression of constitutively active IRF3 
(IRF3-2D), but the wild type IRF3 (wtIRF3) overexpression was much stronger (Figure 
2.1B).  Despite this, IRF3-2D overexpression induced greater expression of Ifit1 and Ccl5, 
two IRF3 downstream target gene, than wtIRF3 (Figure 2.1C and D).  This indicates that 
IRF3-2D can indeed act as a potent constitutively active form of IRF3 in adipocytes.  The 
inability to overexpress IRF3-2D and wtIRF3 to an equal level may be due to a negative 
feedback mechanism initiated by active IRF3 protein.  Although previous studies have 
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not identified any negative feedback mechanism in IRF3 action, IRF4 has been 
implicated in the negative feedback suppression of TLR signaling
167
.  Therefore, we 
hypothesize that IRF3 may be involved in a similar mechanism of negative feedback so 
that active IRF3 levels cannot be grossly overexpressed.   
On the protein level, Western blot experiments showed that both wtIRF3 and 
IRF3-2D protein were highly overexpressed (Figure 2.1E).  It is interesting to note that 
although on the mRNA level, wtIRF3 overexpression is much stronger compared to IRF3-
2D overexpression, on the protein level the extent of overexpression is similar in both 
wtIRF3 and IRF3-2D.  One possible cause for this discrepancy is that the IRF3-2D 
mutation may increase the translational efficiency of the protein in adipocytes.  
Although we did not further explore this possibility, it is a future area to explore in 
studying the regulation of IRF3 activation in adipocytes. 
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Figure 2.１ Lentiviral transduction can overexpress IRF3 in 3T3-L1 adipocytes. 
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Figure 2.1 (Continued). 3T3-L1 adipocytes were transduced with pCDH virus expressing 
EGFP, IRF3, or IRF3-2D seven days after adipogenesis.  A) Live visualization of pCDH-
EGFP transduced cells.  B-D) Q-RTPCR of IRF3 and representative target genes in 
transduced cells *P<0.05.  E) Western blot of transduced cells. 
 
For IRF3 knockdown experiments, a shIRF3 hairpin was cloned into the pSIH1 
lentiviral vector, which encodes GFP in its backbone for easy assessment of transduction 
efficiency.  Lentiviral transduction into 3T3-L1 mature adipocytes was performed seven 
days after differentiation, and transduction efficiency was assessed two days later by 
visualization of GFP (Figure 2.2A).  Eight days after transduction, cells were harvested for 
Q-RTPCR and Western blot experiments.  Both Q-RTPCR and Western blot showed IRF3 
knockdown efficiency to be ~60-70% (Figure 2.2B and C).  We were never able to 
achieve a greater amount of knockdown efficiency, likely due to intrinsic limitations of 
the specific shIRF3 hairpin sequence, since GFP visualization showed very high 
transduction efficiency (Figure 2.2A).  To overcome this limitation, several other shIRF3 
hairpin sequences were assessed but none could achieve a higher knockdown efficiency.  
Therefore we chose to proceed with this shIRF3 hairpin. As discussed later, we used Irf3-
/-
 mouse embryonic fibroblast (MEF)-derived adipocytes as an additional genetic loss-of-
function model to confirm our experimental results. 
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Figure 2.２ Lentiviral transduction of shIRF3 causes knockdown of IRF3 RNA and 
protein levels in 3T3-L1 adipocytes. 
3T3-L1 adipocytes were transduced with pSIH1 virus expressing either shLuc or shIRF3 
seven days after adipogenesis.  A) Live visualization of pSIH1-shLuc transduced cells.  B) 
Q-RTPCR of IRF3 gene expression in transduced cells *P<0.05.  C) Western blot of IRF3 in 
transduced cells. 
 
IRF3 regulates inflammatory genes in adipocytes. 
 We performed transcriptional profiling using Illumina mouse whole genome 
microarrays to assess the effect of IRF3 knockdown and overexpression in adipocytes.  
RNA was harvested from 3T3-L1 adipocytes transduced with IRF3-2D or EGFP control, as 
well as from cells transduced with shIRF3 or shLuc control.  Gene set enrichment 
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analysis (GSEA)
168
 showed that the genes most strongly regulated by IRF3 were those in 
the immune response pathway (Figure 2.3A and B).  This cluster of genes was 
coordinately upregulated by IRF3 overexpression and downregulated by IRF3 
knockdown.  The second most strongly regulated group of genes was involved in GTPase 
activity (Figure 2.3B).  GTPase activation is a part of the inflammatory response 
pathway
169
, and many of the GTPase activity genes identified in the microarray were 
those involved in inflammatory response, indicating that IRF3 is indeed a critical 
regulator of adipocyte inflammatory response. 
 
Up-regulated by IRF3-2D  P-value Down-regulated by shIRF3  P-value 
Immune response  1.3x10
-14
 Immune response 1.4x10
-6
 
GTPase activity 3.3x10
-6
 GTPase activity 4.7x10
-4
 
Cytokine production 2.7x10
-3
 Endocytosis 2.2x10
-2
 
Ubiquitin 3.0x10
-2
 Lipoprotein 2.0x10
-1
 
DNA damage response 4.5x10
-2
 Protein kinase activity 6.0x10
-1
 
Figure 2.３ Immune response genes are among the top group of genes regulated by 
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Figure 2.3 (Continued). IRF3 in adipocytes. 
Whole genome transcriptional profiling of 3T3-L1 adipocytes transduced with pCDH-
EGFP, pCDH-IRF3-2D, pSIH1-shLuc, or pSIH1-shIRF3.  A) Heat map of microarray.  B) Top 
five clusters of genes most highly upregulated by IRF3-2D or downregulated by shIRF3 in 
the microarray identified by GSEA.   
 
To confirm the results from the microarray, Q-RTPCR was performed on several 
of the top genes identified in the immune response cluster, including Ifnβ, Ifit1, Ccl5, 
and Mcp1.  We focused on these four genes because they showed some of the largest 
fold inductions by IRF3-2D overexpression in the microarray, and previous studies in 
immune cells indicate that Ifnβ, Ccl5, and Ifit1 are direct transcriptional targets of IRF369, 
91
.  Indeed, these genes were strongly induced by IRF3 overexpression, while suppressed 
by IRF3 knockdown (Figure 2.4A and B).  Additionally, the expression of these genes in 
epididymal WAT from WT and Irf3-/- mice was assessed; as expected, Irf3-/- WAT showed 
marked reduction in the expression of these genes compared to WT littermates, in both 
chow and HFD-fed conditions (Figure 2.4C and D).   
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Figure 2.４ IRF3 is a regulator of inflammatory gene expression in adipocytes in vitro 
and in vivo. 
Expression analysis of immune response genes by Q-RTPCR in adipocytes.  A) IRF3-2D 
overexpression in 3T3-L1 adipocytes.  B) IRF3 knockdown in 3T3-L1 adipocytes.  C) 
Chow-fed male epididymal WAT. D) HFD-fed male epididymal WAT. *P<0.05 
 
IRF3 deletion does not reduce systemic MCP-1 level. 
 To assess whether loss of IRF3 affects the systemic inflammatory state, the 
serum level of inflammatory cytokine MCP-1 was measured in Irf3
-/-
 and WT mice after 
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16 weeks of either chow or HFD feeding.  As expected, HFD feeding increased the serum 
MCP-1 level since diet induced obesity is known to be an inducer of systemic 
inflammation.  However, Irf3-/- and WT mice showed similar levels of MCP-1 (Figure 2.5), 
indicating that while IRF3 has potent effects at the level of the adipocyte, it may not be 
a critical regulator of the systemic inflammatory state. 
 
Figure 2.５ IRF3 deletion does not affect serum MCP-1 level. 
Fasting serum MCP-1 ELISA, *P<0.05. 
 
IRF3 deletion does not reduce macrophage infiltration in WAT. 
 Adipose tissue-derived MCP-1 is involved in the recruitment of macrophages to 
white adipose tissue in obesity
106, 108
.  Since IRF3 regulates MCP-1 expression in WAT, 
we asked whether deletion of IRF3 would reduce macrophage recruitment under high 
fat fed conditions.  Male Irf3
-/-
 and WT mice were subjected to 16 weeks of high-fat 
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feeding after which their epididymal WAT was harvested and sectioned.  Staining with 
H&E showed no difference in the appearance of adipocytes between the two genotypes 
(Figure 2.6A).  To assess for macrophage infiltration, sections were subjected to 
immunohistochemistry against the macrophage marker F4/80.  Comparison between 
Irf3
-/-
 and WT did not show any difference in the number of crown-like structures, which 
are formed by macrophages surrounding an inflamed adipocyte (Figure 2.6A and B). 
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Figure 2.６ Loss of IRF3 does not affect adipose tissue macrophage infiltration in high 
fat fed mice. 
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Figure 2.6 (Continued). Immunostaining of epididymal WAT from male HFD fed mice.  A) 
H&E and F4/80 staining.  B) Quantification of the number of crown-like structures per 
low power field in F4/80 stained WAT.  N=114 fields per genotype. 
 
Discussion 
 
IRF3 is an important transcriptional regulator of innate immunity.  Therefore we 
hypothesized that IRF3 can also regulate inflammatory gene expression within 
adipocytes.  To this end we employed lentiviral mediated IRF3 knockdown and 
overexpression in 3T3-L1 adipocytes, and then used whole genome microarray analysis 
to find IRF3-regulated genes.  Indeed, the top cluster of genes showing coordinate up-
regulation by IRF3 overexpression and down-regulation by IRF3 knockdown were those 
in the immune response pathway.  This result indicates that IRF3 plays a similar 
transcriptional role in adipocytes as noted by others in immune cells.  Interestingly Kopp 
et al. found that IRF3 is not a mediator of LPS-induced inflammation in 3T3-L1 
adipocytes
170
.  However, in the Western blot used to demonstrate this, Kopp et al. did 
not use a positive control170.  Therefore, this experiment is inconclusive because one 
cannot determine whether the LPS stimulation produced a proper inflammatory 
response in the 3T3-L1 adipocytes, or if the antibody worked properly. 
 To our surprise, further analysis of the inflammatory state of Irf3
-/-
 mice found no 
difference between in the extent of macrophage infiltration of WAT between Irf3-/- mice 
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and WT littermates.  The state of systemic inflammation was also indistinguishable 
between the two genotypes, shown by the similar serum levels of the inflammatory 
cytokine MCP-1 in the serum. 
 We used MCP-1 as a marker of systemic inflammation because it is an important 
chemokine secreted by adipocytes during obesity-induced inflammation.  Increased 
MCP-1 secretion in the adipose tissue recruits monocytes into the adipose tissue, where 
they differentiate into macrophages171, 172.  These macrophages themselves also secrete 
MCP-1 which help build up even more macrophages in the adipose tissue, resulting in a 
positive feedback mechanism perpetuating the increase of adipose tissue macrophages 
during obesity induced inflammation
106
. 
 Although MCP-1 is an important player in inflammation, many other chemokines 
and cytokines are involved in this process.  For instance, leukotriene B4 (LTB4) is 
another chemokine secreted by adipocytes during obesity induced inflammation to 
recruit neutrophils into the adipose tissue
173, 174
.  Mice lacking the LTB4 receptor, BLT1, 
are protected from obesity-induced inflammation and insulin resistance175.  Additionally, 
many inflammatory cytokines are also upregulated during obesity induced inflammation.  
The expression of TNFα, a proinflammatory cytokine, is increased in the adipose tissue 
during obesity, while serum TNFα is also elevated in obese individuals
118, 119, 121, 123
.  
Another proinflammatory cytokine, IL-6 is also elevated in obese individuals and 
reduced with weight loss
96
.  These and other proinflammatory chemokines and 
cytokines may be regulated by IRF3.  Therefore, to gain a more complete understanding 
of the systemic inflammatory state of Irf3
-/-
 mice we will need to measure the serum 
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concentrations of additional chemokines and cytokines.  Since IRF3 is a positive 
regulatory of innate immunity we hypothesize that certain inflammatory markers will be 
decreased in the Irf3-/- mice. 
 Obesity induced inflammation is manifested as both an increase in systemic 
inflammation as well as local adipose tissue inflammation97.  In this study we used the 
number of F4/80+ macrophages as an indicator of adipose tissue inflammatory state.  
Obesity induced inflammation leads to macrophage infiltration in the adipose tissue106.  
These adipose tissue macrophages secrete proinflammatory cytokines such as TNFα, IL-
1β, and IL-6, all of which can impair insulin action, leading to insulin resistance98, 134, 140, 
176, 177
.  However, two groups of macrophages reside in the adipose tissue, namely 
classically activated macrophages (CAMs), also called M1 macrophages, and 
alternatively activated macrophages (AAMs), also called M2 macrophages
158
.  Although 
moth M1 and M2 macrophages are F4/80+, they are differentiated by the expression of 
CD11c.  While M1 macrophages are CD11c+, M2 macrophages are CD11c- 
158, 159, 178
.  M1 
and M2 macrophages are also distinct in their inflammatory milieu.  While M1 
macrophages mainly secrete proinflammatory cytokines such as TNFα and CXCL5, M2 
macrophages secrete a signature of anti-inflammatory cytokines such as IL-10 and IL-
1Ra
158
.   
During obesity-induced inflammation a majority of the adipose tissue infiltrating 
macrophages are M1
159, 178
.  Mice depleted of all CD11c+ macrophages are protected 
from HFD-induced insulin resistance
179
.  These data indicate that the obesity-associated 
inflammation positively correlates with the amount of M1 macrophage infiltration as 
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oppose to that of M2 macrophages.  In this study we assessed the total number of 
adipose tissue macrophages; however, there may still be a difference between the 
number of M1 macrophages between WT and Irf3-/- mice, which will cause a difference 
in adipose tissue inflammation between the two genotypes.  To study this possibility we 
can count the number of F4/80+, CD11c+ and F4/80+, CD11c- cells in the adipose tissue 
of these mice. 
 While we assessed the number of adipose tissue macrophages, many other 
immune cell types have been found to be recruited to the adipose tissue during obesity 
and can contribute to the adipose tissue inflammatory state.  Regulatory T cells (Treg 
cells) secrete anti-inflammatory cytokines that inhibit macrophage recruitment and also 
induce the development of M2 macrophages109, 110.  Clinical studies show that obese 
patients have reduced number of adipose tissue Treg cells
110
.  In contrast CD8+ T helper 
cells (TH1 cells) produce proinflammatory cytokines and are found to be increased in 
obese adipose tissues
110
.  Adipose TH1 cells recruit monocytes to the adipose tissue and 
promote M1 macrophage activation during obesity180. 
 In addition to T cells, B cells are also recruited to the adipose tissue during 
obesity.  Adipose tissue B cells can activate proinflammatory T cells, which in turn 
promote insulin resistance through M1 macrophage activation
111
.  Mast cells are also 
increased in the obese adipose tissue in both human and mouse, and found to play a 
role in obesity induced metabolic disregulation
112
.  Depletion of mast cells in mice 
results in protection from diet induced obesity and improved glucose homeostasis on 
HFD
112
.  Recently, adipose tissue eosinophils have also been found to affect obesity 
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induced inflammation.  Eosinophils are the main producers of anti-inflammatory 
cytokines IL-4 and IL-13 in adipose tissue, which promote the development of M2 
macrophages181.  Obesity results in the reduction of adipose tissue eosinophils, leading 
to a reduction of adipose tissue M2 macrophages.  Mice deficient for eosinophils exhibit 
elevated diet induced inflammation and insulin resistance113. 
 These studies indicate that the inflammatory state of the adipose tissue cannot 
be determined only by the extent of macrophage infiltration.  For a more complete 
picture of the Irf3
-/-
 adipose tissue inflammatory state we can fractionate the adipose 
tissue to collect the stromal vascular fraction and use FACS to sort and count the 
number of different immune cells present, including macrophages, T cells, B cells, mast 
cells, and eosinophils.  Since IRF3 is a positive regulator of inflammatory response we 
hypothesize that there will be a decrease in proinflammatory immune cells and / or an 
increase in anti-inflammatory immune cells in Irf3-/- mice. 
 Our results so far indicate that although IRF3 can activate transcription of 
immune response genes in the adipocyte, it is likely not sufficient to alter the chronic 
inflammatory state associated with obesity.  This finding is consistent with previous 
observations made in Irf3-/- mice, which respond normally to most immune challenges 
other than the aforementioned susceptibility to encephalomyocarditis virus infection 
and resistance to LPS-induced endotoxic shock
157
.  Additionally, Irf3-/- dendritic cells are 
still able to respond to viral RNA stimulation by inducing downstream interferon gene 
expression
156
.  This indicates that other factors must play important roles in the innate 
immune response in the absence of IRF3.  One such transcription factor may be IRF7, 
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which has the closest sequence homology to IRF3 among the nine IRF proteins54.  Similar 
to IRF3, IRF7 is activated by TLR4 signaling and can dimerize with NF-κB to induce 
downstream activation of interferon genes156.  To study this possibility one could look at 
the level of IRF7 expression and activity in 3T3-L1 adipocytes after IRF3 knockdown.  If 
IRF7 is indeed compensating for IRF3 we would expect to see elevated IRF7 expression 
and activation after IRF3 knockdown.  Furthermore one can assess the expression of key 
immune response genes after IRF7 knockdown in cultured Irf3-/- adipocytes, which we 
expect to decrease even more compared to that of Irf3
-/-
 adipocytes.   
We found Irf3-/- mice to exhibit a decrease in intra-adipocyte inflammation.  
However, since IRF3 is deleted in all cells, whether this change is caused by IRF3 action 
within the adipocyte or by the effect of IRF3 in adipose tissue immune cells is unclear.  
We performed in vitro experiments using IRF3 overexpression or knockdown in 3T3-L1 
adipocytes to show that at least a part of the phenotype is due to cell autonomous 
effects in adipocytes.  To definitively answer this question one can use tissue specific 
knockout models of IRF3, specifically IRF3 adipocyte-specific knockout and IRF3 
macrophage-specific knockout mice.  If the decrease in adipocyte inflammation is 
manifested in the IRF3 adipocyte-specific knockout mouse but not in the IRF3 
macrophage-specific knockout model, then one can conclude that this phenotype is due 
to IRF3 action in the adipocyte but not in the macrophage.  Additionally one can study 
IRF3 tissue-specific knockout models in other immune cells present in the adipose tissue 
such as T cells, B cells, and eosinophils to determine whether they are contributors to 
IRF3’s effects on adipocyte inflammation.   
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We can also use bone marrow transplant models to answer this question.  We 
can irradiate WT mice and replace their bone marrow with that from Irf3
-/-
 mice and vice 
versa.  If Irf3-/- mice with WT bone marrow show a decrease in adipocyte inflammation 
while WT mice with Irf3
-/-
 bone marrow do not, then we can conclude that this 
phenotype is not due to the action of IRF3 in hematopoietic-derived cells such as 
macrophages. 
Despite the fact that global immune function appears to be intact in Irf3-/- mice, 
these animals do not have normal metabolic function.  This will be described and 
discussed in the next two chapters.
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Chapter 3  
IRF3 affects energy homeostasis by repressing “browning” of white 
adipose tissue 
54 
 
Introduction 
 
Obesity is a result of the imbalance between energy intake and energy 
expenditure
182
.  When the energy content from food consumption outweighs the 
energy expended in everyday activities to maintain life, the excess energy is stored in 
the body in the form of lipids and leads to an increase in body weight
182
. 
Whole body energy expenditure consists of three different components 
including resting energy expenditure (REE), thermic effect of food (TEF), and activity 
energy expenditure (AEE)
182
.  REE makes up the largest portion of energy expenditure.  
It is the energy expenditure at rest required to maintain life.  TEF is the energy 
expenditure required for the digestion and processing of food.  AEE is the energy 
expenditure associated with physical activity, and is made up of two subcomponents, 
namely exercise energy expenditure and non-exercise activity thermogenesis
182
. 
One component of non-exercise activity thermogenesis is adaptive 
thermogenesis, which is a specific function of BAT.  BAT is found in the interscapular 
depot in mice and supraclavicularly in adult humans
12, 16-18
.  In contrast to WAT, which 
stores excess energy in the form of lipids, BAT dissipates energy through adaptive 
thermogenesis
7
.  The process of adaptive thermogenesis is achieved through the 
function of UCP-1, a BAT-specific protein that localizes to the inner mitochondrial 
membrane.  UCP-1 alters the ATP production process in the mitochondria by allowing 
dissipation of the mitochondrial proton gradient without concomitant ATP synthesis
7, 12
. 
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Thus, in brown adipocytes, a significant percentage of oxygen consumption results in 
heat generation instead of ATP production
12
. 
It was previously believed that white and brown adipocytes originate from a 
common progenitor cell, and clinical evidence point to the possible trans-differentiation 
of brown to white adipocyte and vice versa.  For instance, during cold challenge or 
pharmacological treatment with β3-adrenergic receptor agonists, brown adipocyte-like 
cells that can perform adaptive thermogenesis are found in WAT depots7.  These cells 
are also called “BRITE” or “beige” cells. 
However, recent work suggests that WAT and BAT are actually derived from 
distinct precursor populations.  “Classic” brown adipocytes found in the interscapular 
BAT of mice were found to be derived from Myf5 positive precursor cells that also give 
rise to skeletal muscle cells.  Although WAT and BAT are derived from distinct lineages, 
the origin of the beige cells is still under debate, because these cells appear like brown 
adipocytes, but are not Myf5 positive.  Recent data point to the possibility that they are 
derived from WAT resident mesenchymal stem cells from the white adipocyte lineage, 
but poised for “browning”
25, 26
.  However, whether the exact origins of these cells come 
from resident stem cells, committed preadipocytes, or white adipocytes undergoing 
trans-differentiation remains to be determined. 
Human newborn infants have BAT surrounding the great vessels of the thorax 
that helps them maintain normal body temperature; however, this BAT regresses with 
age
183
.  Until recently, it was believed that humans lose BAT completely by adulthood
183
.  
Recently, however, three groups employed positron-emission tomography and 
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computed tomography (PET-CT) to identify active Ucp1-expressing BAT in the 
supraclavicular region of adult humans
16-18
. Although the exact lineage of the brown 
adipocytes in the supraclavicular BAT is still unclear, these findings validate the 
physiological relevance of BAT in human metabolism, and present BAT, as well as 
adaptive thermogenesis as a valid target for novel anti-obesity treatments in human. 
Chiang et al. identified a potential role for IKKε in thermogenesis.  When kept on 
HFD, IKKε-/- mice were found to have increased food intake coupled with an increase in 
O2 consumption compared to WT, suggesting an overall increase in energy expenditure.  
Additionally, IKKε-/- mice on HFD also show up-regulation of Ucp1 in WAT as well as a 
1.5⁰C increase in body temperature compared to WT, pointing to an increase in 
adaptive thermogenesis95.  IKKε is an immediate upstream kinase of IRF3 in the innate 
immune response pathway
54
.  Upon antigen binding to TLR4, IKKε and TBK1 are 
activated downstream of the MyD88-independent signaling pathway.  Together IKKε 
and TBK1 phosphorylate IRF3, which leads to its dimerization and translocation into the 
nucleus.  Nuclear IRF3 activates the transcription of downstream genes including 
interferon response genes crucial for the innate immune response
54
. 
 Since IRF3 acts downstream of IKKε, we hypothesized that IRF3 may also play a 
role in energy homeostasis.  Therefore we studied the thermogenic phenotype of Irf3
-/-
 
mice as well as the potential development of beige cells in Irf3
-/-
 WAT. 
 
Materials and methods 
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Animals 
 Please refer to Materials and Methods in Chapter 2 to see a complete 
description of animal housing conditions and diet, as well as breeding schemes.  
 
Body weight and composition 
 Body weight of mice was recorded weekly beginning at three weeks of age.  
Body mass composition was measured using an Echo-MRI 3-in-1 Composition Analyzer 
(Echo Medical Systems, Houston, TX) at 20 weeks of age.  Individual conscious animals 
were placed in a glass tube and placed in the MRI for brief scanning.   
 For tissue weight, each tissue was carefully dissected and weighed on a Mettler 
Toledo AG140 analytical scale. 
 
Food intake 
 Mice food intake was measured daily over a one week period at 21 weeks of age.  
Mice were housed individually and provided the same amount of either chow diet or 
HFD ad libitum.  The amount of food placed into the cage was weighed everyday and 
the amount remaining was weighed again 24hr later, and the daily food intake was 
calculated by taking the difference between the two values.  Food was replaced every 
day after weighing.  Food intake was measured at the end of the daily light cycle.  Data 
were analyzed using two-way ANOVA. 
 
CLAMS 
58 
 
Mice metabolic rate was measured by indirect calorimetry in open-circuit 
Oxymax chambers that are a component of the Comprehensive Lab Animal Monitoring 
System (CLAMS, Columbus Instruments).  All mice were acclimatized to monitoring 
cages for 48 hours prior to the beginning of an additional 72 hours of hourly automated 
recordings of physiological parameters.  Mice were housed singly and maintained at 
73⁰F (22.8⁰C) under a 12:12 light dark cycle.  Food and water were available ad libitum.  
Data were analyzed using two-way ANOVA. 
 
Cold exposure 
 Mice were individually housed and given free access to food and water.  Cages 
were placed in an air ventilated 4⁰C cooler and subjected to 12hr light : dark conditions. 
 Body temperature of each mouse was measured individually using a rectal probe 
attached to a Precision Thermometer 4600 (YSI). 
 
Thermoneutral treatment 
 Ten week old male mice were housed 5 per cage and given free access to food 
and water.  Cages were placed in an air ventilated 30⁰C incubator and subjected to 12hr 
light : dark conditions.  Tissues were harvested 3 weeks later. 
 
Tissue histology 
 Please refer to the Materials and Methods section in Chapter 2 for a complete 
description of procedures used for tissue histology.  
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Inguinal WAT SVF isolation 
Inguinal WAT was dissected from pairs of WT vs. Irf3-/- littermates at 5-6 weeks 
of age.  The SVF was dissociated from adipocytes by 1hr incubation in PBS buffer 
supplemented with Collagenase D (Roche) and Dispase II (Roche).  The SVF was further 
purified by filtering through a cell strainer.  The resulting cells were cultured in 1:1 
DMEM/F12 media with Glutamax (Invitrogen) supplemented with 10% FBS and 
Pen/Strep.  Primary SVF cells were maintained no more than five passages. 
For adipogenic differentiation, cells were pretreated with 20ng/ml BMP-4 at one 
day before confluency.  Adipogenesis was induced one day post confluency with an 
adipogenic cocktail containing dexamethasone, insulin, isobutylmethylxanthine, and 
rosiglitazone.  Cells were induced for 48 hours, after which they were maintained in 
DMEM/F12/Glutamax/FBS/Pen/Strep media supplemented with 5ug/ml insulin.  
Adipocytes were harvested for experiments 7 days after adipogenesis. 
 
Q-PCR 
 Please refer to the Materials and Methods section in Chapter 2 for a complete 
description of procedures for Q-RTPCR. 
 
Statistical analysis 
 Please refer to the Materials and Methods section in Chapter 2 for a complete 
description of methods used for statistical analysis. 
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Results 
 
Male Irf3
-/-
 mice have reduced fat mass on HFD. 
 To determine the role of IRF3 in metabolism, we characterized the metabolic 
phenotype of Irf3-/- mice.  When kept on chow diet, the body weights of both male and 
female Irf3
-/-
 mice were indistinguishable from their WT littermates (Figure 3.1A and B).  
Body composition analysis was performed using Echo-MRI after 16 weeks of chow diet, 
and revealed no differences in either the lean or fat mass distribution between the two 
genotypes (Figure 3.1C and D). 
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Figure 3.１  Irf3-/- mice do not show a body weight or body mass composition 
phenotype on chow diet. 
A-B) Weekly body weight of chow-fed A) male and B) female mice.  C-D) Body mass 
composition of chow-fed mice as measured by MRI of A) males and B) females.  N=9-12. 
 
A second cohort of mice was challenged with HFD (58% kcal from fat).  After 24 
weeks of HFD feeding, there was no divergence in the overall body weight between Irf3-
/-
 mice and WT littermates in both male and females (Figure 3.2A and B).  However, after 
20 weeks of high-fat feeding male Irf3-/- mice showed a slight but statistically significant 
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decrease in fat mass and an increase in lean mass compared to WT littermates (Figure 
3.2C).  Consistent with this observation, high fat fed female Irf3
-/-
 mice also displayed a 
trend toward decreased fat mass and increased lean mass, but this did not reach 
statistical significance (Figure 3.2D). 
 
Figure 3.２  Irf3-/- mice have decreased fat mass and increased lean mass on HFD. 
A-B) Weekly body weight of HFD-fed A) male and B) female mice.  C-D) Body 
composition analysis of HFD-fed mice as measured by Echo-MRI of A) males and B) 
females.  N=9-12 *P<0.05. 
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To determine whether IRF3 affects the mass of different fat depots, inguinal 
WAT, epididymal WAT, and BAT were dissected and weighed on an analytical scale.  The 
weights of these three fat pads were indistinguishable between Irf3-/- mice and WT 
littermates (Figure 3.3A and B).  The spleen was used as a negative control organ 
because it is a non-metabolic tissue in which IRF3 is highly expressed.  
  
Figure 3.３  IRF3 deletion does not affect the mass of fat depots. 
 A) Tissue weight of 12 week-old male chow-fed mice.  BAT: brown adipose tissue, I-
WAT: inguinal white adipose tissue, E-WAT: epididymal white adipose tissue.  B) Body 
weight of the mice used in panel A.  N=6. 
 
We thus had to reconcile the observations that the MRI showed decreased 
adiposity, while actual fat pad weights (and body weight) were unchanged. This led us 
to hypothesize that lack of IRF3 may promote the development of brown adipocyte-like 
cells within the WAT. These cells, also called ‘beige’ or ‘BRITE’ cells, can develop within 
white fat pads in certain conditions, such as cold exposure or β3-adrenergic stimulation.  
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Classic BAT, as well as these brown-adipose like cells, have reduced lipid content and 
can possibly be recognized as lean mass by the Echo-MRI machine. 
 
Irf3
-/-
 mice develop beige cells in the inguinal WAT. 
 To determine whether Irf3-/- mice are predisposed to develop beige cells in WAT, 
subcutaneous adipose tissue from the inguinal depot was dissected from 12 week-old 
male mice maintained at room temperature (22.8⁰C), sectioned and stained with 
hematoxylin-eosin (H&E).  One simple way to identify beige cells is to look for the 
presence of multilocularity, which is a hallmark of brown adipocytes.  Indeed, the 
inguinal WAT of Irf3
-/-
 mice had many clusters of multilocular adipocytes, while the 
inguinal WAT of WT mice contained predominantly unilocular adipocytes (Figure 3.4A).  
Interestingly, the histological appearance of classic interscapular BAT from Irf3
-/-
 mice 
was not different from that of WT mice (Figure 3.4B).  Inguinal WAT and BAT sections 
were subjected to immunohistochemistry using a UCP-1 antibody.  Again, many clusters 
of UCP-1 positive adipocytes were found in the inguinal WAT from Irf3-/- mice, while 
very few were present in the inguinal WAT from WT mice (Figure 3.4A).  No difference 
was found in the number of UCP-1 positive adipocytes in the interscapular BAT of Irf3-/- 
and WT mice (Figure 3.4B).  
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Figure 3.４  Irf3-/- mice have increased beige cells in inguinal WAT. 
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Figure 3.4 (Continued). Tissue section immunostaining from chow fed male mice kept at 
ambient temperature.  A) Inguinal WAT.  B) Interscapular BAT.  
 
Previous research has shown that cold challenge can stimulate the development 
of beige cells in the inguinal WAT of mice12, 19.  To determine whether IRF3 deletion can 
further enhance the development of beige cells under cold challenged conditions, ten 
week-old male mice were exposed to 4⁰C for three days, and their inguinal WAT and 
BAT was analyzed histologically.  Interestingly, H&E staining revealed that multilocular 
cells were equally abundant in the inguinal WAT of both Irf3-/- and WT mice, while 
immunohistochemistry against UCP-1 showed a similar amount of UCP-1 positive 
adipocytes between the two groups (Figure 3.5A).  The interscapular BAT also did not 
differ histologically between the two genotypes (Figure 3.5B).  These results suggest 
that IRF3 represses the formation of beige cells under basal (i.e. warm) conditions, and 
that cold exposure relieves this inhibition.   
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Figure 3.５ Loss of IRF3 does not increase the number of beige cells in the inguinal 
WAT under cold challenged conditions. 
Tissue section immunostaining of chow fed male mice after 3 days exposure to 4⁰C 
conditions.  A) Inguinal WAT B) interscapular BAT.   
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Although laboratory mice are studied at room temperature, their thermoneutral 
temperature is actually 30⁰C.  To determine if deletion of IRF3 can stimulate the 
development of beige cells in mice at thermoneutrality, ten week old Irf3-/- and WT mice 
were housed in a 30⁰C chamber for 3 weeks and their inguinal WAT and BAT were 
studied. H&E staining showed that the inguinal WAT of Irf3-/- mice contained clusters of 
multilocular adipocytes, while the inguinal WAT from WT mice was made up of 
predominantly unilocular adipocytes.  Immunohistochemistry against UCP-1 showed 
that many of the multilocular cells detected in Irf3
-/-
 inguinal WAT were UCP-1 positive, 
while barely any UCP-1 positive cells could be detected in WT inguinal WAT (Figure 3.6A).  
H&E staining of interscapular BAT showed that exposure to thermoneutral conditions 
increased lipid accumulation in both Irf3-/- and WT mice, while no difference was found 
in the abundance of UCP-1 positive cells (Figure 3.6B).  Together these results indicate 
that IRF3 prevents the development of beige cells in the inguinal WAT under basal 
conditions, and that deletion of IRF3 is sufficient to release this inhibition. 
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Figure 3.６ Irf3-/- mice have increased beige cells under thermoneutral conditions. 
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Figure 3.6 (Continued). Tissue section immunostaining of chow fed male mice after 3 
weeks exposure to 30⁰C.  A) Inguinal WAT B) interscapular BAT.   
 
Brown adipocyte genes are induced in the white adipocytes of Irf3
-/-
 mice. 
 We next assessed whether these histologically identified beige cells express 
brown adipocyte signature genes in the inguinal WAT and BAT of Irf3
-/-
 and WT mice.  
We assessed the expression of Prdm16, a critical determinant of brown adipogenesis24-
26, 28
; Pgc1α and Ucp1, both important players in adaptive thermogenesis
12, 16, 17, 26
; 
Cox7a1, an indicator of mitochondrial activity184; and CideA, a regulator of Ucp1 
activity
185
.  Key brown adipocyte genes were significantly up-regulated in both tissues of 
Irf3
-/-
 mice compared to WT (Figure 3.7).  These results suggest that the histologically 
identified beige cells in the Irf3
-/-
 inguinal WAT are indeed functional. 
 
Figure 3.７ Loss of IRF3 elevates the expression of brown adipocyte-selective genes in 
white and brown adipose tissue. 
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Figure 3.7 (Continued). Q-RTPCR of brown adipocyte genes.  A) Inguinal WAT from HFD-
fed male mice.  B) Interscapular BAT from HFD-fed male mice.  N=4, *P<0.05. 
 
In addition to studying inguinal WAT tissue, an in vitro model was also employed 
to determine whether the observed “browning” effect was cell autonomous.  The 
stromal-vascular fraction (SVF) of inguinal WAT was fractionated from Irf3
-/-
 and WT 
mice.  Pre-adipocytes from the SVF were briefly propagated and then differentiated into 
adipocytes.  This model allows us to study the role of IRF3 in beige cell development 
independent of other tissues.  Since IRF3 is anti-adipogenic, we need to ensure both Irf3-
/-
 and WT cells are equally differentiated.  Pre-adipocytes were treated with BMP-4 
before adipogenic differentiation, and rosiglitazone was applied during the 
differentiation process to drive adipogenesis to completion.  Differentiated adipocytes 
were treated with Oil-Red-R, which stains neutral lipids, to assess the extent of 
differentiation (Figure 3.8A).  The expression of key adipocyte genes was also measured 
using Q-RTPCR (Figure 3.8B).  Results from both Oil-Red-O and gene expression analysis 
indicate that both Irf3
-/-
 and WT cells underwent adipogenic differentiation to an equal 
extent.  
The expression of key brown adipocyte selective genes was assessed by Q-RTPCR 
in cultured SVF-derived adipocytes.  In agreement with results from adipose tissue, 
these key brown adipocyte selective genes were significantly upregulated in Irf3
-/-
 
adipocytes compared to WT (Figure 3.8C). 
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Figure 3.8 (Continued). Brown adipocyte-selective genes are elevated in cultured Irf3
-/-
 
adipocytes. 
Inguinal SVF-derived adipocytes 7 days after adipogenic differentiation.  A) Oil-Red-O 
staining.  Whole field scan (top) and 10X magnified image (bottom).  B) Q-RTPCR of 
adipocyte genes.  C) Q-RTPCR of brown adipocyte selective genes.  N=4 *P<0.05. 
 
Irf3
-/-
 mice are partially protected from cold challenge. 
 One of the major functions of brown adipocytes is to perform adaptive 
thermogenesis.  An increase in the number of beige cells in Irf3-/- mice should promote 
adaptive thermogenesis, and thus ameliorate the drop in body temperature of these 
mice during cold exposure.  Twelve week-old male Irf3-/- and WT mice were exposed to 
4⁰C, and the change in their rectal temperatures was measured over time.  Although 
both Irf3-/- and WT mice dropped to 31⁰C after two hours, the rate of drop in 
temperature was slower in Irf3
-/-
 mice compared to WT, suggesting at least partial 
protection from cold (Figure 3.9).   
One may expect “browning” of the white adipocyte to confer greater protection 
from cold induced body temperature drop for Irf3-/- mice than what we observed.  
However, adaptive thermogenesis is just one mechanism of thermogenesis under cold 
challenge.  For instance, shivering is another mechanism to maintain physiological body 
temperature
186
.  We hypothesize that the increase in the number of beige adipocytes 
allows Irf3
-/-
 mice to confer faster response to cold challenge in maintaining their body 
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temperature.  However, as time progresses other mechanisms of thermogenesis such as 
shivering allow WT mice to eventually reach the same body temperature. 
 
Figure 3.９ Irf3-/- mice are partially protected from cold-induced drop in body 
temperature. 
Rectal temperature of 12 week old male mice exposed to 4⁰C.  N=6, *P<0.05. 
 
Irf3
-/-
 mice exhibit increased food intake and energy expenditure on HFD. 
 If Irf3
-/-
 mice have increased numbers of beige cells at room temperature, we 
might expect them to show increased energy expenditure. These mice were placed in 
open-circuit Oxymax chambers that are a component of the Comprehensive Lab Animal 
Monitoring System (CLAMS) to monitor their metabolic rate.  No difference was 
observed in the amount of physical activity between Irf3
-/-
 and WT mice (Figure 3.10B).  
However, Irf3
-/-
 mice displayed significantly increased O2 consumption and CO2 
production compared to WT, which together caused a marked shift in the respiratory 
exchange ratio (RER) (Figure 3.10C-E), suggesting a movement away from glucose as a 
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main source of fuel towards a fatty acid burning scheme.  This is consistent with an 
increase in beige cells, which rely on fatty acid oxidation for adaptive thermogenesis. 
Irf3
-/-
 mice displayed increased body heat compared to WT, again consistent with 
increased adaptive thermogenesis (Figure 3.10F).  Given that energy expenditure was 
increased, we were puzzled to note that the Irf3-/- mice did not weigh less than WT 
littermates. We therefore measured daily food intake in male mice after 18 weeks of 
HFD feeding.  Irf3-/- mice consumed approximately 0.4 g more food everyday compared 
to WT littermates (Figure 3.10A), which likely counterbalances the effect of the 
increased energy expenditure on body mass.  Although the decrease in RER in Irf3-/- 
mice indicates that they are burning a smaller percentage of glucose in favor of fatty 
acids, their increase in food intake suggests that overall, Irf3-/- mice are burning more 
energy than WT mice, only with a change in preference for the source of energy. 
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Figure 3.１０  Irf3-/- mice have increased food intake and energy expenditure on HFD. 
A) Daily food intake and cumulative food intake (inset) of male mice after 18 weeks on 
HFD, *P<0.05.  B-F) Metabolic rate as measured by CLAMS  B) Movement, C) O2  
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Figure 3.10 (Continued). consumption, D) CO2 production, E) Respiratory exchange ratio, 
F) Total body heat output.  N=8. 
 
Discussion 
 
We found IRF3 to be a potent suppressor of beige cell development in inguinal 
WAT (Figure 3.11).  Specifically, Irf3
-/-
 mice were found to have increased numbers of 
beige cells in the inguinal WAT compared to WT mice at both room temperature and 
thermoneutral conditions, but not in cold challenged conditions.  Interscapular BAT 
showed no histological difference between Irf3-/- and WT mice at any condition.  This 
suggests that IRF3 may act as a brake for the development of WAT resident beige cells. 
Under basal conditions deletion of IRF3 allows the development of resident precursor 
cells into mature beige cells, while cold challenge overcomes the brake put into place by 
IRF3.  This would explain why beige cell number and thermogenic capacity are not 
different between WT and Irf3
-/-
 mice after prolonged exposure to 4⁰C. 
 
Figure 3.１１ IRF3 regulates energy homeostasis by inhibiting adipocyte browning.  
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Thermogenesis
Cold
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Further characterization under HFD-fed conditions show that Irf3
-/-
 mice exhibit 
increased food intake, increase energy expenditure, and a shift away from glucose 
toward fatty acid as a source of fuel.  These characteristics are all consistent with 
enhanced adaptive thermogenesis due to an increase in the number of beige cells.  
Lastly, adaptive thermogenesis by these beige cells also conferred short-term protection 
from cold-induced body temperature drop in Irf3-/- mice.  Additional ex vivo experiments 
will need to be performed to assess the functional characteristics of the beige cells 
appearing in the WAT of Irf3-/- mice, such as the rate of cellular respiration and 
mitochondrial density, which should both be increased due to a more brown adipocyte-
like phenotype. 
One of the unexplained phenotypes observed in the Irf3
-/-
 mice is a small but 
significant increase in lean mass accompanied by a similar decrease in fat mass 
compared to WT littermates when fed HFD.  One possible explanation for this 
observation is the inability of the Echo-MRI analyzer to properly classify BAT.  The Echo-
MRI analyzer distinguishes fat mass from lean mass via the difference in their density
187, 
188.  Because BAT is denser than WAT we hypothesize that BAT may be recognized as 
lean mass by the Echo-MRI analyzer.  Since the Irf3
-/-
 mice exhibit browning of the WAT, 
this phenotype may be manifested as an increase in lean mass with decrease in fat mass.  
One way to test this hypothesis is to analyze pure BAT and see if the Echo-MRI analyzer 
recognizes it as lean mass.   
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One might wonder if Irf3-/- mice exhibit increased “browning” of the WAT, why 
did we not detect an elevation of brown adipocyte specific genes in the microarray of 
3T3-L1 adipocytes after lentiviral mediated IRF3 knockdown (Figure 2.3)?  This 
inconsistency can be explained by the inability of 3T3-L1 adipocytes to become brown 
adipocytes.  Among the many in vitro adipocyte models, 3T3-L1 cells are one of the most 
white adipocyte-like
189, 190
.  Key brown adipocyte selective genes such as Ucp1 and 
Pgc1α are undetectable in 3T3-L1 adipocytes (data not shown).  Due to this reason, we 
employed an alternative in vitro model of adipocytes, namely preadipocytes isolated 
from the SVF fraction of the inguinal fat pad, to study the cell autonomous effect of IRF3 
on adipocyte “browning” (Figure 3.8). 
We observed increased “browning” of the WAT in chow fed Irf3-/- mice; however, 
we found increased thermogenesis in high fat-fed Irf3
-/-
 mice.  This may be due to the 
fact that under the metabolic challenge of HFD a small increase in energy expenditure 
may be more easily detectable.  Further experiments are underway to study adipocyte 
“browning” in high fat-fed Irf3-/- mice.  These are similar experiments performed to 
study adipocyte browning in chow diet-fed mice, such as tissue histology to look for 
multilocular and Ucp1 positive cells in the inguinal WAT.  We hypothesize that lack of 
IRF3 will also induce “browning” of WAT in high fat-fed mice. 
One interesting phenotype of the Irf3
-/-
 mice is their increased food intake 
compared to WT littermates.  This phenotype cannot be explained by increase adipocyte 
“browning.”  One adipokine that regulates food intake is leptin.  Leptin reports 
peripheral nutritional information such as the energy store level of the adipose tissue to 
80 
 
the central nervous system3.  Leptin expression increases with feeding and decreases 
with starvation.  Elevation of leptin levels acts as a satiety signal and initiates a negative 
feedback loop to the hypothalamus to suppress food intake1, 3, 191.  When leptin levels 
drop, the hypothalamus initiates a feeding response to increase energy intake
3, 192
.  
Studies of the ob/ob mouse, which is deficient of the obese gene encoding leptin, show 
massive weight gain and hyperphagia
191, 193, 194
.  Alternatively, the db/db mouse, which 
expresses a mutant leptin receptor effectively abolishing leptin signaling, exhibit 
massive adipose tissue depots and produces excessive leptin
193, 195
.  Similar to the ob/ob 
mouse, db/db mice are also extremely obese, hyperphagic, as well as diabetic193, 195.   
Leptin action is mediated by receptors present in the brain as well as peripheral 
organs such as the pancreas, liver, and the immune system3, 196.  Leptin receptor binding 
in the hypothalamus results in downstream activation of the JAK-STAT3 signaling 
pathway, leading to an increase in anorexigenic neuropeptides such as 
proopiomelanocortin (POMC), as well as the expression of orexigenic neuropeptides 
neuropeptide Y (NPY) and agouti-related protein (AgRP)196, 197.  Therefore, we 
hypothesize that IRF3 may be affecting food intake through its effects on adipose leptin 
expression.  To test this hypothesis we can begin by measuring the serum leptin levels of 
WT and Irf3
-/-
 mice.  We expect serum leptin to be decreased in Irf3
-/-
 mice.  Additionally 
we can inject leptin into WT and Irf3
-/-
 mice.  If a difference in leptin level is causing the 
differences in food intake then leptin injection should equalize this difference. 
An alternative possibility is that IRF3 plays a role in the central nervous system 
that regulates feeding behavior.  We have previously shown that IRF3 is expressed in the 
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brain (Figure 1.2B), and previous studies have also shown that IRF3 plays an important 
role in immune response in the brain
198, 199
.  IRF3 was found to be a mediator of 
interferon response to corneal infection with herpes simplex virus198 as well as response 
to viral double stranded RNA in astrocytes
199
.  Interestingly, IRF3 and the interferon 
response pathway which it regulates has also been implicated in protecting the brain 
against ischemic injury post stroke
200
.  Therefore it is possible that IRF3 plays a role on 
the central nervous system to regulate feeding behavior.   
One possible way to test this hypothesis is to knockout IRF3 specifically in the 
hypothalamus and assess whether this still leads to an increase in food intake.  To 
perform this experiment we can first create a floxed IRF3 mouse model, then inject 
adeno-associated virus (AAV) expressing the Cre protein into the hypothalamus of the 
floxed IRF3 mouse
201
.  This will result in a mouse with IRF3 deleted only in the 
hypothalamus.  If IRF3 is indeed acting on the hypothalamus to regulate food intake 
then this mouse will exhibit increase food intake just as in the Irf3
-/-
 mouse. 
Further studies could focus on fully characterizing the role of IRF3 in beige cell 
development.  We do not know which stage of beige cell development IRF3 is acting 
upon, but it is intriguing that Prdm16, one of the earliest known transcriptional 
activators of the brown as well as beige cell fate, is altered by loss of IRF3.  This suggests 
that IRF3 plays a role very early in the developmental process of beige adipogenesis.  
Since IRF3 is a transcription factor it is possible that it is transcriptionally regulating the 
expression of Prdm16.  One possible way to test this is to perform a luciferase reporter 
assay of the Prdm16 promoter with IRF3 overexpression.  If IRF3 is transcriptionally 
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regulating the IRF3 promoter we would expect IRF3 overexpression to reduce Prdm16 
promoter luciferase activity. 
In addition to possible transcription regulation of brown adipocyte selective 
genes, it is also possible that IRF3 affects the adipose sympathetic tone, and thus lack of 
IRF3 may lead to activation of the sympathetic tone, which can lead to increased 
adaptive thermogenesis.  Activation of the sympathetic tone can lead to increased 
noradrenaline release in the adipose tissue202, 203.  Noradrenaline can stimulate the 
expression of brown adipocyte selective genes such as Ucp1 and Pgc1α in adipocytes 
and thus result in “browning” of white adipocytes204-206.  To test this hypothesis we can 
measure the level of noradrenaline in the WAT of WT and Irf3
-/-
 mice, and we would 
expect to find higher noradrenaline levels in Irf3-/- mice. 
Our results also suggest that cold might inhibit the expression or activity of IRF3 
in WAT, a possibility that we are currently investigating (Figure 3.11).  We are 
performing two experiments to test this hypothesis.  We investigated the expression of 
IRF3 mRNA in inguinal WAT after cold exposure but did not detect any change (data not 
shown).  However, in immune cells it is known that IRF3 is regulated post-translationally 
but not transcriptionally69, therefore it is possible that this is also true in the adipocyte.  
We plan to study IRF3 protein level in inguinal WAT after cold exposure to determine 
whether cold challenge decreases IRF3 protein.  It is also possible that cold exposure 
affects the phosphorylation state of IRF3, and we plan to use mass spectrometry to 
determine the phosphorylation state of adipose IRF3 before and after cold exposure. 
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Chapter 4  
IRF3 hinders adipocyte glucose homeostasis through 
transcriptional regulation of GLUT4 
84 
 
Introduction 
  
IRF3 is an important transcriptional regulator of the innate immune response.  It 
acts downstream of TLR4 to initiate interferon response to pathogen infection.  Upon 
antigen recognition, TLR4 signaling leads to the downstream activation of IKKε and TBK1, 
which act together to phosphorylate IRF3, leading to its dimerization and nuclear 
translocation.  Nuclear IRF3 then binds to the promoter and activates transcription of 
interferon response genes such as Ccl5 and Ifnβ, ultimately resulting in the activation of 
the interferon response pathway
54
. 
 Characterization of Ikkε
-/-
 mice show them to be protected from HFD-induced 
obesity.  Additionally they exhibit decreased fasting serum insulin as well as better 
glucose tolerance compared to WT mice on HFD conditions.  Interestingly, studies of the 
Tlr4
-/-
 mice also found them to be more insulin tolerant compared to WT mice on HFD
95
.   
Adipose tissue is an important regulator of insulin stimulated glucose uptake.  It 
influences the glucose uptake ability of peripheral tissues by secreting adipokines that 
act on muscle and liver
7
.  For instance, adiponectin, a major adipokine, which has been 
found to be down-regulated during obesity, enhances insulin sensitivity
207-209
.  
Conversely, adipose tissue can also secrete insulin-desensitizing cytokines.  TNFα, a pro-
inflammatory cytokine secreted by WAT, is up-regulated during obesity and decreases 
insulin sensitivity125.  Resistin, another major cytokine found to be up-regulated in 
obesity, hinders glucose uptake while elevating hepatic glucose output
210, 211
. 
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In addition to influencing liver and skeletal muscle glucose homeostasis, adipose 
tissue itself also accounts for ~10-15% of systemic glucose uptake via insulin stimulated 
glucose uptake into adipocytes1.  Following nutritional intake, pancreatic β-cells secrete 
insulin in response to elevated glucose in the circulation
212
.  Insulin stimulates glucose 
uptake in peripheral tissues, including skeletal muscle and adipose tissue212.  Insulin 
binds to the insulin receptor (IR) on the plasma membrane of target cells, resulting in IR 
dimerization and auto-phosphorylation213-215.  Activated IR subsequently phosphorylates 
insulin receptor substrates IRS1 and IRS2, which then recruit Pl-3 kinase (PI-3k) to the 
cell surface216, 217.  PI-3k converts phosphatidylinositol 4, 5 bisphosphate (PIP2) to 
phosphatidylinositol 3, 4, 5 triphosphate (PIP3)
218, 219
, resulting in the activation of 3-
phosphoinositide dependent kinase (Pdk1), which ultimately leads to protein kinase B 
(Akt) phosphorylation
220, 221
.  Akt promotes the exocytosis of glucose transporter 4 
(Glut4) containing vesicles to the plasma membrane, allowing the import of glucose into 
the cell via an ATP-independent, facilitative diffusion mechanism
221-225
.  Imported 
glucose serves distinct purposes in different tissues.  In skeletal muscle cells, glucose is 
metabolized to generate ATP, while in the adipose tissue excess glucose is stored as 
triglycerides212. 
Glut4 is a 12-transmembrane protein that is the major transporter responsible 
for insulin stimulated glucose transport in adipocyte and muscle cells
226
.  Under basal 
conditions Glut4 undergoes idle cycling among several intracellular compartments 
including Glut4 storage vesicles (GSV), endosomal recycling compartment (ERC), and 
Trans-golgi network (TGN)
226
.  Without insulin stimulation, Glut4 is prevented from 
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translocation to the plasma membrane (PM) by proteins that promote intracellular 
retention such as AS160 and Sortilin.  Under insulin stimulation Glut4 vesicles bud from 
GSV, quickly translocate to the cell surface and fuses with the plasma membrane227.  
While new Glut4 protein synthesized by the endoplasmic reticulum are modified in the 
TGN, then sorted directly into GSV.  Post insulin stimulation cell surface Glut4 is recycled 
via clathrin-mediated endocytosis or cholesterol-dependent, clathrin-independent 
endocytosis226.  Endocytosed Glut4 accumulates in the endosomal recycling 
compartment (ERC).  From the ERC a small amount of Glut4 is sorted back to the plasma 
membrane, while a majority of the Glut4 is sorted into the GSV or TGN where it 
undergoes idle cycling until the next insulin stimulation
226
. 
In addition to the tight intracellular regulation of its localization, GLUT4 is also 
regulated transcriptionally
228
.  GLUT4 is encoded by the Slc2a4 gene.  Mice studies show 
that Slc2a4 transcription is decreased in obesity and T2D models229, 230.  Many 
transcription factors have been found to upregulate Slc2a4 expression in adipocytes, 
including sterol response element binding protein-1c (Srebp-1c) and liver X receptor α 
(LXRα)
228
.  Additionally thyroid hormone receptor α1 (TRα1) and kruppel-like factor 15 
(Klf15) can regulate Slc2a4 expression in both muscle and adipocytes44, 228.  Conversely, 
tumor necrosis factor α (Tnfα), nuclear factor 1 (Nf-1), and nuclear factor-kappa B (Nf-κB) 
are negative regulators of Slc2a4 expression
132, 176, 228
.   
Since IRF3 acts downstream of both TLR4 and IKKε we hypothesized that it too, 
may play a role in glucose homeostasis.  To this end we characterized the metabolic 
phenotype of Irf3
-/-
 mice.  Skeletal muscle and adipose tissue are the two major players 
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in peripheral glucose uptake, which is tightly regulated by insulin secreted from 
pancreatic β cells.  Both tissues utilize glucose in different ways; skeletal muscle cells 
metabolize glucose to generate ATP, while in the adipose tissue excess glucose is stored 
as triglycerides
7, 222
.  Therefore, to elucidate the role of IRF3 in glucose homeostasis we 
must carefully dissect the different roles played by each tissue, which can best be done 
by studying tissue-specific knockout models of IRF3.  However, at present the floxed 
IRF3 mouse model is unavailable.  To overcome this difficulty we employed in vitro 
models of IRF3 overexpression and knockdown to supplement in vivo data from global 
knockout mice.  Specifically, we chose to study IRF3 in cultured adipocytes because IRF3 
is highly expressed and its expression is induced during adipogenic differentiation.  This 
suggests that IRF3 may play a critical role in mature adipocytes, an excellent model for 
studies of cellular glucose uptake. 
 
Materials and methods 
 
Animals 
 Please refer to Materials and Methods in Chapter 2 to see a complete 
description of animal housing conditions and diet, as well as breeding schemes.  
 
Insulin tolerance test 
 Mice were fasted for 6hr then injected intraperitoneally with human insulin 
(Humulin, Eli Lilly).  Insulin doses range from 0.6-1 units/kg body weight depending on 
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whether the animals were on chow diet or HFD.  The blood glucose level was measured 
before and at multiple time points after insulin injection by taking tail bleeds from each 
mouse.  Glucose readings were taken with OneTouch handheld glucometers (Johnson 
and Johnson). 
 
Glucose tolerance test 
 Mice were fasted overnight and fasting serum was collected from cheek bleed 
using a 5.5mm sterile animal lancet (Goldenrod).  Mice were then injected 
intraperitoneally with a solution of 20% glucose at a dose of 1g/kg body weight.  The 
blood glucose level was measured before and at multiple time points after insulin 
injection by taking tail bleeds from each mouse. 
 
Serum cytokine measurements 
 Mice were fasted overnight and fasting serum was collected from cheek bleed 
using a 5.5mm sterile animal lancet (Goldenrod).  Fasting serum was separated from 
whole blood by centrifugation at 3000 rpm for 5 min at 4⁰C in BD Microtainer serum 
separator tubes (BD Bioscience #365956).  Serum adiponectin was measured using the 
Chemicon Mouse Adiponectin ELISA Kit (Millipore #EZMADP-60K). 
 
3T3-L1 adipocytes 
 Please refer to the Materials and Methods section in Chapter 2 for a complete 
description of the procedures followed for 3T3-L1 cell culture and adipogenesis. 
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IRF3 knockdown and overexpression in 3T3-L1 adipocytes 
 Please refer to the Materials and Methods section in Chapter 2 for a complete 
description of the procedures used for lentiviral production and lentiviral mediated IRF3 
overexpression and knockdown in 3T3-L1 adipocytes. 
 
MEFs 
Pairs of WT vs. Irf3
-/-
 embryos from the same litter were harvested on E13.5.  
After trypsinization and dissociation the fibroblasts are plated in high glucose 
DMEM/FBS.  The 3T3 protocol was followed for immortalization
231
.  Briefly, cells were 
subcultured every 3 days at a density of 1.17 million cells per 10cm dish, and after 30 
passages MEFs were considered immortalized.   
For adipogenic differentiation, immortalized WT and Irf3-/- MEFs were 
transduced with retrovirus encoding Pparγ.  After puromycin selection for transduced 
cells, differentiation was induced with an adipogenic cocktail, including dexamethasone, 
insulin, isobutylmethylxanthine, and rosiglitazone.  After 3 days of induction cells were 
maintained in high glucose DMEM/FBS until further experiments. 
 
Glucose uptake assay 
3T3-L1 adipocytes and MEF-derived adipocytes were subjected to glucose 
uptake assay either 10 days after adipogenic differentiation or 8 days after lentiviral 
transduction.  Cells were serum-starved in high glucose DMEM for 4 hours and then 
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stimulated with 100nM insulin or vehicle for 15 min in KRH buffer at 37°C, after which 
[
3
H] 2-deoxyglucose (2-DG) were added to the cells and incubated for 4 min.  Glucose 
uptake is terminated by the addition of ice cold KRH with 25mM glucose and 10uM 
cytochalasin B (Sigma Aldrich).  Excess [
3
H] 2-DG was eliminated by repeated washing 
with ice cold KRH buffer.  Cell lysates were solubilized in 0.1%SDS, mixed with EcoLite 
scintillation fluid (MP Biomedicals), and [
3
H] 2-DG uptake was measured by liquid 
scintillation counting.  All glucose uptake experiments were performed with six 
replicates for each sample. 
 
Lipogenesis assay 
3T3-L1 adipocytes and MEF-derived adipocytes were subjected to lipogenesis 
assay either 10 days after adipogenic differentiation or 8 days after lentiviral 
transduction.  Cells were serum-starved in low glucose DMEM (Invitrogen) 
supplemented with 0.5% FBS for 3 hours then treated with 100nM insulin for 15 min at 
37°C.  Lipogenesis was then stimulated by adding [14C] glucose and terminated after 45 
min by repeated washing with ice cold PBS.  Cells are harvested in PBS and mixed with 
EcoLite scintillation fluid.  After overnight phase separation, 200ul of the lipid top layer 
is extracted for scintillation counting.  All lipogenesis experiments were performed with 
six replicates for each sample. 
 
Q-PCR 
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 Please refer to the Materials and Methods section in Chapter 2 for a complete 
description of the procedures used for Q-RTPCR. 
 
Tissue western blot 
 Mice were fasted overnight before tissue harvest.  Tissues were frozen in liquid 
nitrogen immediately after dissection.  For Western blots, tissues were homogenized in 
RIPA buffer supplemented with MiniComplete Protease Inhibitor (Roche) and 
phosphatase inhibitor cocktail II (Boston BioProducts).  Total protein was quantified 
using the DC method (Bio-Rad) and 50ug of each protein sample was used for Western 
blot.  Each sample was mixed with Laemmli buffer and boiled for 5 min at 95⁰C.  
Samples were loaded into 10% polyacrylamide denaturing gels (Bio-Rad).  Each gel was 
transferred onto PVDF membrane (Millipore).  After transfer each membrane was 
blocked in 5% milk in PBS-T for 1 hr then incubated in primary antibody overnight at 4⁰C.  
On the next day each membrane is washed in PBS-T before incubating with secondary 
antibody for 1 hr at room temperature.  Lastly each membrane was washed in PBS-T 
before being developed with SuperSignal West Pico Maximum Sensitivity Substrate 
(Pierce) and exposed to film.   
 
Luciferase assay 
 3T3-L1 adipocytes were transfected using the Amaxa Nucleofection II 
transfection device following manufacturer’s protocol 7 days after adipogenesis.  Briefly, 
one 10cm plate of adipocytes were trypsinized, pelleted, and then resuspended in 100μl 
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of Amaxa Nucleofector Solution V (Lonza #VCA-1003).  Cell solution was then mixed 
with DNA containing 4μg pGL3 basic vector, 2μg pCDH IRF3 overexpression vector, and 
50ng of pRL Renilla luciferase control reporter vector.  The resulting mixture was placed 
in the transfection device and transfected with program A33.  Transfected cells were 
immediately replated in high glucose DMEM with 10% FBS.  Cells were allowed to attach 
overnight and the media was replaced 18hr later. 
 Luciferase assay was performed 48hr after transfection using Dual Luciferase 
Reporter Assay Kit (Promega #E1960) following the manufacturer’s protocol.  Luciferase 
activity was measured using FluoStar Optima fluorescence plate reader (BMG Labtech).  
Luciferase activity was normalized with Renilla, and all experiments were performed in 
quadruplicates. 
 
Statistical analysis 
 Please refer to the Materials and Methods section in Chapter 2 for a complete 
description of the procedures followed for statistical analysis. 
 
Results 
 
Male Irf3
-/-
 mice exhibit enhanced glucose metabolism on HFD. 
We sought to determine whether IRF3 plays a role in glucose homeostasis. When 
kept on a chow diet, male Irf3
-/-
 and WT mice at 22 weeks of age were found to be 
equally glucose tolerant (Figure 4.1A).  However, after 22 weeks of HFD, male Irf3
-/-
 mice 
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exhibited an enhanced ability to clear glucose compared to WT in a glucose tolerance 
test (GTT) (Figure 4.1B). 
 
Figure 4.１Male Irf3-/- mice have enhanced glucose tolerance on HFD. 
Glucose tolerance test of male mice on A) chow or B) HFD.  N=9-12, *P<0.05. 
 
To test whether the improved glucose tolerance of Irf3 
-/-
 mice is associated with 
increased insulin sensitivity, we performed insulin tolerance tests (ITT). At 21 weeks of 
age, chow fed male Irf3
-/-
 mice displayed comparable insulin tolerance as their WT 
littermates (Figure 4.2A).  However, male Irf3-/- mice maintained on 21 weeks of HFD 
showed significantly improved insulin tolerance compared to WT (Figure 4.2B). 
 
Male chow
0 15 30 60 90 120
0
100
200
300
400 Irf3-/-
WT
Time (min)
Se
ru
m
 
gl
u
c
o
s
e
 
[m
g/
dL
]
Male HFD
0 15 30 60 90 120
0
200
400
600 Irf3-/-
WT
*
*
*
*
Time (min)
Se
ru
m
 
gl
u
c
o
s
e
 
[m
g/
dL
]
A B
Male chow
0 15 30 60 90 120
0
50
100
150
200
250 Irf3-/-
WT
Time (min)
Se
ru
m
 
gl
u
c
o
s
e 
[m
g/
dL
]
Male HFD
0 20 40 60 90 120
0
100
200
300 Irf3-/-
*
WT
* *
Time (min)
Se
ru
m
 
gl
u
c
o
s
e 
[m
g/
dL
]
A B
Figure 4.２ 
94 
 
Figure 4.2 (Continued). Male Irf3
-/-
 mice have enhanced insulin tolerance on HFD. 
Insulin tolerance test of male mice on A) chow or B) HFD.  N=9-12, *P<0.05. 
 
Fasting serum glucose and insulin levels were measured in male mice after an 
overnight fast.  For both chow and HFD cohorts, no difference was observed in the 
serum glucose levels of Irf3
-/-
 and WT mice (Figure 4.3A).  Irf3
-/-
 and WT mice kept on 
chow diet exhibited similar levels of fasting serum insulin.  Under HFD conditions, 
however, Irf3
-/-
 mice had significantly lower serum insulin compared to their WT 
littermates, consistent with their improved performance in the GTT and ITT (Figure 4.3B). 
 
Figure 4.３ Male Irf3-/- mice have reduced fasting serum insulin on HFD. 
Fasting serum A) glucose or B) insulin of chow and HFD fed male mice.  N=9-12, *P<0.05. 
 
Female Irf3
-/-
 mice do not display enhanced glucose metabolism on HFD. 
Interestingly, the enhanced glucose metabolism exhibited by male Irf3-/- mice on 
HFD, was not seen in female mice.  GTT performed on female mice after 22 weeks of 
HFD did not show any difference in glucose tolerance between Irf3-/- mice and their WT 
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littermates (Figure 4.4A).  Similarly, female Irf3-/- and WT mice had similar insulin 
tolerance (Figure 4.4B).  The fasting glucose and insulin levels were also 
indistinguishable between female high fat-fed WT and Irf3-/- mice (data not shown). 
 
Figure 4.４ Female Irf3-/- mice do not display enhanced glucose homeostasis on HFD. 
A) Glucose tolerance test and B) Insulin tolerance test of female mice on HFD.  N=9-12, 
*P<0.05. 
 
IRF3 hinders insulin action in 3T3-L1 adipocytes. 
 Glucose homeostasis is regulated through the interaction of peripheral tissues 
such as the adipose tissue, liver, and muscle.  The enhanced glucose homeostasis 
phenotype in male Irf3
-/-
 mice on HFD may be due to the role of IRF3 in any or all of 
these three organs.  Because IRF3 is highly expressed in adipocytes and its expression 
level is elevated in mature 3T3-L1 adipocytes, we hypothesized that at least part of this 
phenotype is due to IRF3’s role in adipocytes.  One way to test this hypothesis in vivo is 
to study the metabolic phenotype of adipocyte-specific IRF3 knockout mice.  
Unfortunately, conditional (i.e. floxed) Irf3 mice are not currently available, so we used 
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an in vitro adipocyte model to study the role of IRF3 in cell autonomous adipocyte 
glucose homeostasis. 
 Mature 3T3-L1 adipocytes were transduced with lentiviral constructs mediating 
IRF3 overexpression or knockdown as described earlier.  Insulin-stimulated glucose 
uptake and lipogenesis assays were performed 10 days later.  While both wtIRF3 and 
IRF3-2D overexpression did not change basal glucose uptake, insulin-stimulated glucose 
uptake was significantly reduced by IRF3-2D overexpression.  Similarly, wtIRF3 
overexpression resulted in a trend toward reduced insulin-stimulated glucose uptake 
that did not reach statistical significance (Figure 4.5A). Conversely, shRNA mediated IRF3 
knockdown resulted in enhanced insulin-stimulated glucose uptake, while basal glucose 
uptake was not affected (Figure 4.5B).   
 In addition to glucose uptake, insulin also stimulates lipogenesis in fat cells.  
Lentiviral-mediated overexpression of both wtIRF3 and IRF3-2D reduced insulin-
stimulated lipogenesis, while basal lipogenesis remained unchanged (Figure 4.5C).  
Consistent with these observations, knockdown of IRF3 resulted in improved insulin-
stimulated lipogenesis (Figure 4.5D).  These data indicate IRF3 plays an important role in 
adipocyte insulin action and glucose homeostasis.  Thus, the enhanced glucose 
metabolism observed in HFD-fed Irf3
-/-
 mice is at least in part due to the role of IRF3 in 
the adipose tissue. 
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Figure 4.５ IRF3 reduces insulin-stimulated glucose uptake in 3T3-L1 adipocytes. 
A-B) Glucose uptake assay in 3T3-L1 adipocytes 8 days after lentiviral mediated IRF3 A) 
overexpression or B) knockdown.  C-D) Lipogenesis assay in 3T3-L1 adipocytes 8 days 
after lentiviral mediated IRF3 C) overexpression or D) knockdown.  N=6, *P<0.05 
 
Adipocytes derived from Irf3
-/-
 MEFs exhibit enhanced insulin action. 
 Although shRNA-mediated IRF3 knockdown in 3T3-L1 adipocytes results in 
enhanced glucose uptake and lipogenesis, it is possible that this effect is due to off-
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additional in vitro model, namely immortalized mouse embryonic fibroblasts (MEFs) 
isolated from WT and Irf3
-/-
 mice and differentiated into adipocytes in vitro.   
Since IRF3 is known to be anti-adipogenic, WT and Irf3-/- MEFs may not 
differentiate equally.  To overcome this problem, MEFs were transduced with a 
retrovirus overexpressing PPARγ and treated with rosiglitazone, a potent PPARγ ligand, 
during adipogenic differentiation.  Together these two measures drive adipogenesis to 
completion, as measured by Oil-Red-O staining, which showed that both WT and Irf3-/- 
MEFs achieved equal levels of differentiation (Figure 4.6A).  Additionally, the expression 
of representative adipocyte genes were measured by Q-RTPCR and showed no 
difference between adipocytes derived from WT and Irf3
-/-
 MEFs (Figure 4.6B). 
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Figure 4.６ WT and Irf3-/- MEFs achieved equal levels of adipogenesis. 
MEF derived adipocytes 7 days after adipogenic differentiation.  A) Oil-Red-O staining.  
Whole field scan (top) and 10X magnified image (bottom).  B) Q-RTPCR of adipocyte 
genes, N=4. 
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Glucose uptake and lipogenesis assays were performed using MEF-derived 
adipocytes.  Irf3
-/-
 adipocytes showed enhanced insulin-stimulated glucose uptake 
compared to WT, while basal glucose uptake was unchanged (Figure 4.7A).  To confirm 
that this is an IRF3-specific effect, Irf3
-/-
 MEF adipocytes were rescued by reintroducing 
IRF3-2D or EGFP control via lentiviral transduction.  Reintroduction of IRF3-2D in Irf3-/- 
MEF adipocytes diminished insulin-stimulated glucose uptake compared to EGFP control 
(Figure 4.7B). 
Additionally, lipogenesis was also assessed in Irf3
-/-
 MEF adipocytes.  Irf3
-/-
 
adipocytes showed improved insulin-stimulated lipogenesis compared to WT, while 
basal lipogenesis was unaffected (Figure 4.7C).  In the rescue experiment, Irf3
-/-
 
adipocytes overexpressing IRF3-2D showed reduced insulin-stimulated lipogenesis 
compared to those overexpressing EGFP control (Figure 4.7D).  These data are entirely 
consistent with and validate the observations made in 3T3-L1 adipocytes.  Taken 
together, these results indicate that IRF3 is a suppressor of insulin-stimulated glucose 
homeostasis in adipocytes. 
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Figure 4.７ Adipocytes derived Irf3-/- MEFs have enhanced insulin-stimulated glucose 
uptake. 
A-B) Glucose uptake assay in MEF-derived adipocytes adipocytes A) 10 days after 
adipogenic differentiation or B) 8 days after IRF3 overexpression.  C-D) Lipogenesis assay 
in MEF-derived adipocytes C) 10 days after adipogenic differentiation or D) 8 days after 
IRF3 overexpression.  N=6, *P<0.05. 
 
IRF3 affects glucose uptake at different doses of insulin. 
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IRF3 knockdown using a range of insulin doses from 1nM to 100nM.  Regardless of the 
dose of insulin used, IRF3 knockdown enhanced insulin-stimulated glucose uptake 
(Figure 4.8).  This was interesting to us because proportionate increase in glucose 
uptake at all insulin levels after a manipulation has been suggested to indicate a role for 
that factor in late insulin action, post-insulin receptor (IR) activation232.   
 
Figure 4.８ IRF3 knockdown enhances glucose uptake at different doses of insulin. 
Dose-dependent insulin-stimulated glucose uptake in 3T3-L1 adipocytes.  A) 1nM insulin 
B) 10nM insulin C) 100nM insulin and D) a composite view across all insulin doses.  N=6, 
*P<0.05. 
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The insulin signaling pathway involves many different nodes
221
.  Insulin binding 
leads to dimerization and auto-phosphorylation of IR.  Phosphorylated IR subsequently 
phosphorylates IRS1 and IRS2, which then recruit PI-3k to the cell surface.  PI-3k 
converts PIP2 to PIP3, leading to the downstream activation Pdk1, which ultimately leads 
to Akt phosphorylation and activation.  Activated Akt recruits the Glut4 glucose 
transporter to the cell surface to facilitate glucose transport into the cell212, 221, 224.  To 
determine whether IRF3 regulates the insulin signaling pathway we used Western blots 
to detect the abundance of phosphorylated Akt in the visceral adipose tissue of high fat-
fed male Irf3
-/-
 and WT mice five minutes after intraperitoneal insulin injection.  No 
difference was found in the amount of phosphorylated Akt between Irf3-/- and WT mice 
(data not shown).  Since Akt is a late node in the insulin signaling pathway, this data 
suggests that IRF3 is not affecting the insulin signaling pathway in adipocytes.  However, 
we are still studying the effect of IRF3 on pre-Akt nodes, such as possible changes in IRS 
phosphorylation and activation. 
 
Irf3
-/-
 WAT has increased levels of Glut4. 
 Since IRF3 is a transcription factor, it is likely that IRF3 is hampering insulin 
stimulated glucose homeostasis by transcriptionally regulating target genes involved in 
insulin action.  The results from the microarray analysis in 3T3-L1 adipocytes (Figure 2.1) 
were used to find such target genes.  An analysis was performed to search for genes 
that are regulated in opposite directions by IRF3-2D and shIRF3, and are also known to 
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be players in insulin-stimulated glucose uptake.  The two top candidates that emerged 
were Adipoq and Slc2a4.  Both genes were down-regulated after IRF3-2D 
overexpression and up-regulated by shIRF3 in 3T3-L1 adipocytes.  Adipoq encodes the 
hormone adiponectin, which has an insulin-sensitizing function.  Slc2a4 encodes the 
Glut4 glucose transporter, which is necessary for insulin-stimulated glucose uptake in 
adipocytes.   
 To confirm the microarray results, Q-RTPCR was used to determine the 
expression of Adipoq and Slc2a4.  Indeed, both genes were potently down-regulated by 
IRF3-2D overexpression and significantly up-regulated after IRF3 knockdown in 3T3-L1 
adipocytes (Figure 4.9A and B).  Additionally, the expression of these genes was also 
assessed in mouse WAT.  In agreement with the in vitro data, both Adipoq and Slc2a4 
were up-regulated in WAT from Irf3
-/-
 mice compared to WT in both chow and high fat-
fed conditions (Figure 4.9C and D).   
While Adipoq is an adipocyte-specific gene, Slc2a4 is also expressed in skeletal 
muscle, which is a key organ in insulin-stimulated glucose homeostasis.  To determine 
whether IRF3 is a regulator of Slc2a4 in skeletal muscle, the expression of Slc2a4 in 
muscle was assessed by Q-RTPCR and no difference was found between Irf3-/- and WT 
mice on HFD (Figure 4.9E).  This result indicates that the effect of IRF3 on global insulin-
stimulated glucose homeostasis is likely not mediated via regulation of Slc2a4 
expression in skeletal muscle. 
Although Slc2a4 expression is up-regulated in Irf3
-/-
 WAT, Glut4 protein levels 
must also be elevated to confer an insulin-sensitizing phenotype.  Indeed, Western 
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blotting showed that Glut4 protein was significantly elevated in WAT of Irf3-/- mice 
compared to WT littermates under HFD conditions (Figure 4.9F).  WT and Irf3
-/-
 MEF 
derived adipocytes were used as an in vitro model, and Glut4 protein was also markedly 
increased in Irf3
-/-
 cells compared to WT (Figure 4.9G).   
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Figure 4.９ IRF3 regulates Slc2a4 expression in adipocytes. 
A-E) Q-RTPCR of Slc2a4 and Adipoq expression in A) 3T3-L1 adipocytes after IRF3 
overexpression, B) 3T3-L1 adipocytes after IRF3 knockdown, C) epididymal WAT of 
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Figure 4.9 (Continued). chow-fed male mice, D) epididymal WAT of HFD-fed male mice, 
E) skeletal muscle of HFD-fed male mice. N=4, *P<0.05.  F) Western blot of epididymal 
WAT from HFD-fed male mice, G) Western blot of MEF-derived adipocytes with WAT 
from the GLUT4 transgenic mouse as positive control. 
 
Irf3
-/-
 mice do not show increased serum adiponectin. 
 To study adiponectin protein levels, serum adiponectin was measured via ELISA 
in both chow and HFD-fed mice.  Our results show the expected reduction in serum 
adiponectin level after HFD.  However, adiponectin levels are not elevated in Irf3
-/-
 mice, 
and in fact are somewhat lower than in WT animals, suggesting that IRF3’s role in 
insulin-stimulated glucose homeostasis is not mediated by systemic changes in serum 
adiponectin. 
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Figure 4.10 (Continued). Serum adiponectin is not elevated in Irf3
-/-
 mice. 
Fasting serum adiponectin of chow and HFD fed male mice.  N=8, *P<0.05. 
 
IRF3 transcriptionally regulates the Slc2a4 promoter. 
 Because IRF3 is a transcription factor, it is possible that it exerts its effect on 
Glut4 expression by directly transcriptional regulation of the Slc2a4 gene.  Analysis of 
the Slc2a4 proximal promoter using the Mulan multiple sequence local alignment and 
visualization tool (http://mulan.decode.org) identified several potential ISRE sites, with 
the most proximal ISRE located at 801 base pairs upstream of the transcription start site.  
To test whether IRF3 regulates Slc2a4 via this ISRE site, promoter luciferase constructs 
containing 808 base pairs of the Slc2a4 promoter were cloned and luciferase assays 
were performed in 3T3-L1 adipocytes after wtIRF3 or IRF3-2D overexpression.  
Compared to EGFP control, overexpression of wtIRF3 significantly reduced luciferase 
activity driven by the Slc2a4 proximal promoter, and IRF3-2D reduced luciferase activity 
to an even greater extent.  When the putative ISRE site was deleted, neither wtIRF3 nor 
IRF3-2D overexpression reduced luciferase activity (Figure 4.11).  These results indicate 
IRF3 hinders glucose homeostasis at least in part by transcriptionally regulating the 
expression of Glut4 in adipocytes. 
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Figure 4.１１ IRF3 regulates the Slc2a4 promoter. 
Luciferase promoter assay of the Slc2a4 promoter after EGFP or IRF3 overexpression in 
3T3-L1 adipocytes.  pGL3 control: pGL3 basic empty vector, pGL3-Slc2a4: pGL3 vector 
containing the Slc2a4 proximal promoter including the ISRE site at -801bp, pGL3-Slc2a4Δ: 
pGL3 vector containing 789bp of the Slc2a4 proximal promoter so that the ISRE site is 
deleted.  N=4, *P<0.05.  
 
Discussion 
  
Here we characterized the role of IRF3 in glucose homeostasis.  Analysis of Irf3
-/-
 
mice after high fat feeding showed enhanced glucose and insulin tolerance in the GTT 
and ITT, accompanied by decreased fasting serum insulin levels.  Unlike the Tlr4
-/-
 and 
the Ikkε-/- mice, Irf3-/- mice did not have reduced body weight.  Even though Irf3-/- mice 
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did exhibit a small decrease in fat mass and complementary increase in lean mass, which 
we proposed above is correlated with an increase in beige adipocytes, such a small 
change in body composition is not likely to be sufficient to increase systemic insulin 
sensitivity to such a degree.  Furthermore our results in Chapter 2 suggested that IRF3 
deletion did not alter macrophage infiltration of WAT or the whole body systemic 
inflammatory state.  Hence the enhanced glucose homeostasis in Irf3
-/-
 mice is not likely 
due to reduced inflammation.  As a result, we hypothesized that IRF3 may hinder 
glucose homeostasis through an additional mechanism in white adipose tissue. 
 Using 3T3-L1 adipocytes and MEF-derived adipocytes as in vitro adipocyte 
models, we found IRF3 overexpression to reduce insulin-stimulated glucose uptake and 
lipogenesis, and IRF3 knockdown or knockout to have the opposite effect.  Subsequent 
Q-RTPCR experiments found Slc2a4 mRNA and the Glut4 protein it encodes to be 
reduced in adipocytes after IRF3 overexpression and induced by IRF3 knockdown; Irf3-/- 
WAT also showed elevated Glut4 levels.  A luciferase assay was used to show that IRF3 
suppresses Slc2a4 expression via an ISRE site 801 base pairs upstream of the Slc2a4 
transcriptional start site (Figure 4.12). 
 
Figure 4.１２IRF3 suppresses adipocyte glucose uptake by transcriptionally 
downregulating adipose Glut4. 
  
IRF3 Glut4 Glucose uptake
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One intriguing question arising from these results is the sexual dimorphism 
observed in the enhanced insulin handling phenotype of the Irf3
-/-
 mice.  A possible 
explanation for this discrepancy is the differences in hormones between the male and 
female mice
233
.  Specifically, estrogen, the primary female sex hormone has been 
implicated to play a role in whole body insulin sensitivity.  Treating postmenopausal 
women with estrogen increased their insulin sensitivity as measured by both GTT and 
ITT; however, another study showed that estrogen can cause insulin resistance in young 
women
234, 235
.  Treating insulin receptor mutant mice with estrogen enhances their 
resistance to oxidative stress, while ovariectomy leads to increased susceptibility to 
oxidative stress, which has been shown to contribute to insulin resistance
127, 236
.  To test 
whether the sexual dimorphism of the Irf3-/- mice insulin handling phenotype results 
from a difference in estrogen levels, we can remove the effect of estrogen by 
performing ovariectomy on WT and Irf3-/- female mice, then determine whether the Irf3-
/-
 mice exhibit enhanced insulin sensitivity on HFD compared to WT. 
It is still unknown whether IRF3 regulates the Slc2a4 promoter by direct binding 
or via an intermediate protein, although the involvement of the ISRE makes direct 
binding the most likely scenario.  We would like to use chromatin immunoprecipitation 
(ChIP) to confirm direct binding, but we have not been able to locate a ChIP-grade 
mouse IRF3 antibody.  An alternative strategy would be to perform ChIP after ectopic 
expression of a tagged form of IRF3 in 3T3-L1 adipocytes.  We will design primers 
against computationally predicted ISRE regions in the Slc2a4 promoter and perform PCR 
on the ChIP products.  Regions directly bound by IRF3 should be successfully amplified. 
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 The Glut4 glucose transporter is regulated transcriptionally as well as post-
translationally
228, 237
.  Under basal conditions GLUT4 resides intracellularly, but upon 
insulin stimulation, Glut4 containing vesicles fuse with the plasma membrane facilitating 
contact with extracellular glucose
237
.  It would be interesting to determine whether 
increased Glut4 protein in Irf3-/- adipocytes also translates to increased Glut4 transport 
to the plasma membrane.  To test this hypothesis we can use GFP-tagged Glut4 to 
visualize Glut4 location in the adipocyte.  Glut4-GFP and IRF3-2D will be overexpressed 
in 3T3-L1 adipocytes and Glut4 localization will be visualized under a confocal 
microscope.  If IRF3 is a regulator of Glut4 translocation then we will see differences in 
Glut4 trafficking in IRF3-2D overexpressing cells compared to negative control. 
 Another intriguing question is the tissue specific regulation of Glut4 expression 
by IRF3 only in adipocytes but not in muscle.  One way this can occur is that IRF3 
regulation of Glut4 requires cofactors that are only present in adipocytes but not in 
muscle.  For instance it is known that there are transcription factors that regulate Glut4 
only in adipocytes such as Srebp-1c and LXRα228.  Alternatively transcription factors that 
regulate Glut4 only in muscle include muscle-specific Glut4 enhancer factor (GEF) and 
myogenic bHLH factors (MyoD)223, 228.  To test this hypothesis we can perform 
immunoprecipitation (IP) of IRF3 followed by mass spectrometry.  Performing this 
experiment in both muscle and adipocytes will determine the different cofactors bound 
to IRF3 in each tissue.   
These results will also help us answer the question of whether IRF3 directly binds 
to the Slc2a4 promoter or regulates Glut4 via an intermediate transcription factor, 
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which binds the Slc2a4 promoter.  By studying the list of cofactors bound to IRF3 in 
adipocytes we can look for transcription factors that are previously known to be direct 
transcription regulators of Glut4.  If such a factor is identified we can further test 
whether this factor is required for IRF3 regulation of Glut4 by knocking down this factor 
in 3T3-L1 adipocytes followed by IRF3-2D overexpression and testing whether IRF3-2D 
can still cause insulin resistance compared to negative control. 
 In addition to Slc2a4, we also identified Adipoq to be down-regulated by IRF3 
overexpression and up-regulated in IRF3 knockdown and knockout adipocytes.  
However, when we measured serum adiponectin levels in Irf3-/- mice, we did not see the 
expected increase.  Adiponectin is an adipokine that’s secreted by the adipose tissue 
and acts on the liver and muscle.  It enhances insulin sensitivity, leading to a decrease in 
hepatic gluconeogenesis and an increase in skeletal muscle glucose uptake
238-240
.  
Adiponectin binding to its receptors in liver and muscle leads to downstream activation 
of Ampk and Pparα
238
.  Ampk activation inhibits gluconeogenesis while stimulating fatty 
acid oxidation, and Pparα activation stimulates energy dissipation through increased 
fatty acid oxidation and by lowering oxidative stress and inflammation
238, 241
. 
Circulating adiponectin is found in three different isoforms: global trimers, low-
molecular weight hexamers, and high-molecular weight 18-mers
238
.  Metabolic diseases 
such as T2D, hypertension, atherosclerosis, and endothelial dysfunction are associated 
with low circulating adiponectin levels
238, 240, 242, 243
.  However, the risk for T2D is 
inversely associated with only high molecular weight adiponectin
242, 244, 245
.  In addition, 
only the high molecular weight isoform of adiponectin is associated with insulin 
114 
 
sensitizing effects, while the other two isoforms are implicated in the central effects of 
adiponectin action
238
.  Therefore it is still possible that IRF3 may influence glucose 
homeostasis through affecting the level of high molecular weight adiponectin, but the 
ELISA assay used in this study was unable to distinguish between the different isoforms 
of adiponectin. 
 In summary, we identified IRF3 to be a transcriptional suppressor of the 
expression of the Glut4 glucose transporter in adipocytes.  Deletion of IRF3 resulted in 
up to four-fold up-regulation of the gene and protein, which points to the importance of 
IRF3 in glucose homeostasis.  
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Chapter 5  
Conclusions and future directions 
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Conclusions 
In the past 20 years there has been a growing recognition of the close link 
between the immune and the metabolic systems
97
.  Obesity has been found to be 
associated with chronic low-grade systemic inflammation as well as inflammation of 
peripheral metabolic tissues including adipose tissue, liver, and muscle.  This state of 
inflammation is a crucial contributing factor to the comorbidities of obesity, including 
insulin resistance and T2D
97
. 
Numerous studies have shown that obesity results in elevated expression of 
inflammatory cytokines such as TNF-α, IL-6, IL-10, and IL-1β in the adipose tissue, which 
contribute to obesity-induced insulin resistance
4
.  Additionally, many kinases involved in 
the proinflammatory signaling pathway, such as JNK, IKKβ, and PKC are also activated 
during obesity and act to promote insulin resistance
141, 143-145
.  However, few studies 
have looked into the transcriptional pathways that regulate the immune-metabolic 
interaction.  Here we show that IRF3, an important transcription factor in the viral-
mediated interferon response pathway, is a player in this transcriptional pathway 
crosstalk. 
First of all, using whole genome microarray and Q-RTPCR analysis we found IRF3 
to be a potent inducer of immune response genes in adipocytes.  Unexpectedly, 
however, we did not see altered MCP-1 levels or a decrease in the extent of 
macrophage infiltration in the WAT of Irf3-/- mice.  Despite this, we did in fact find that 
IRF3 has potent effects on adipose tissue biology and metabolism. 
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Upon examination of the adipose tissue of Irf3-/- mice, we found IRF3 to be a 
potential suppressor of beige cell development from poised precursors in inguinal WAT.  
Specifically, Irf3-/- mice were found to have increased number of UCP-1-expressing beige 
cells in the inguinal WAT compared to WT mice at room temperature and 
thermoneutral conditions, but not in cold challenged conditions.  When exposed to cold 
challenge, Irf3
-/-
 mice exhibited short-term protection from a sharp drop in body 
temperature.  These mice also exhibited increased food intake and energy expenditure 
as well as a shift away from glucose toward fatty acid as a source of fuel in Irf3
-/-
 mice on 
HFD.  Together these data suggest that IRF3 is a regulator of energy homeostasis by 
suppressing the “browning” of adipocytes.   
 Lastly we found IRF3 to be a transcriptional regulator of glucose homeostasis.  
Specifically, Irf3
-/-
 mice exhibited enhanced insulin sensitivity and glucose tolerance on 
HFD.  In vitro experiments in cultured adipocytes found this phenomenon to be at least 
partially due to an adipocyte-specific role of IRF3 to suppress the expression of Glut4 
(Figure 5.1). 
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Figure 5.１IRF3 regulates glucose and energy homeostasis by suppressing adipocyte 
browning and Glut4 expression. 
  
Because of the close link between the immune and the metabolic systems, is it 
possible that some of the phenotypes manifested in the Irf3
-/-
 mice are in part due to 
IRF3’s role in immune response?  Nguyen et al. recently showed that M2 macrophages 
are required to sustain adaptive thermogenesis
246
.  They found cold exposure to be an 
inducer of adipocyte M2 macrophages.  These macrophages produce catecholamines 
that promote upregulation of Pgc1α, Ucp1, and Acsl1.  Disruption of the IL-4/IL-13 
pathway, which is required for M2 macrophage polarization, resulted in blunted 
adaptive thermogenesis, and thus these mice were unable to maintain core body 
temperature in response to cold challenge246. 
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 IRF3 is a strong positive regulator of M1 macrophage activation54, 61.  Therefore 
Irf3
-/-
 mice may exhibit elevated M2 macrophage polarization accompanied by 
decreased M1 macrophage polarization in the adipose tissue.  This can lead to increased 
catecholamine in the adipose tissue, which may lead to the increased thermogenesis 
and adipocyte “browning” phenotype of the Irf3-/- mice.  To determine whether M2 
macrophage activation is indeed contributing to the increased thermogenesis and 
adipocyte “browning” in Irf3-/- mice, we can study whether there is increased M2 
macrophage activation in the adipose tissue of Irf3
-/-
 mice.  This can be done by 
fractionating the adipose tissue and using FACS sorting to count the number of M1 
macrophages, which are CD11c+ and M2 macrophages, which are CD11c-.  If Irf3
-/-
 mice 
have increased CD11c- macrophages in the white adipose tissue then M2 macrophage 
polarization is a contributing factor to the increased beige adipocyte phenotype in Irf3
-/-
 
mice. 
 In this study we observed both increased adipose tissue “browning” and 
enhanced glucose handling in Irf3-/- mice.  Although we have identified increased Glut4 
expression as a direct cause for enhanced glucose handling, it is still possible that the 
increase in adipose tissue “browning” is also a contributor to the glucose handling 
phenotype.  Previous studies have shown that diabetes is associated with decreased 
expression of the brown adipocyte-selective gene Pgc1α
247
, while resveratrol treatment, 
which increases Pgc1α activity, protects mice from diet induced obesity and insulin 
resistance
248
.  Clinical observations also show that insulin resistant patients exhibit 
reduction in a panel of brown adipogenic genes including Pgc1α, Ucp1, Rxrγ, etc
249
. 
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 To determine how much the increase in adipocyte “browning” is contributing to 
the enhanced insulin sensitivity in Irf3
-/-
 mice, we can assess how much lack of IRF3 
increases insulin sensitivity in the absence of browning.  This can be achieved by mating 
Irf3
-/-
 mice onto an adipocyte-specific Prdm16 knockout background.  Since lack of 
Prdm16 in the adipocyte will inhibit the development of brown adipocytes, we can 
compare the insulin sensitivity of the double-knockout mice with those expressing IRF3 
to determine the extent to which IRF3 can affect insulin sensitivity without adipocyte 
“browning”. 
  
Future directions 
One might wonder whether hyperactivation of IRF3 is involved in the onset of 
obesity since obesity is closely associated with the dysregulation of glucose and energy 
homeostasis.  We have studied the expression of IRF3 in lean and obese mice and found 
no difference, consistent with the observation that IRF3 is constitutively expressed, and 
is not typically regulated at the transcriptional level
57
.  IRF3 is, however, highly regulated 
by post-translational modifications75.  Latent IRF3 resides in the cytoplasm, and under 
stimulation it is phosphorylated at the C-terminus, dimerizes, and translocates into the 
nucleus to activate transcription of downstream genes63, 68, 69, 71.  Therefore the best way 
to study IRF3 activity is to look at its phosphorylation or translocation.  Unfortunately 
there is currently no usable mouse-specific antibody on the market that specifically 
detects phosphorylated IRF3.  We have also attempted to isolate the nuclear fraction 
from adipose tissue to detect nuclear IRF3.  However, since obese adipose tissue is filled 
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with infiltrating macrophages, which also highly express IRF3, one must fractionate the 
adipose tissue to separate the adipocytes from the macrophages.  Due to the low 
amount of nuclear protein in the obese adipocyte and the loss of yield from the 
fractionation process we have, as yet, been unable to detect adipose nuclear IRF3.  We 
are now pursuing a mass-spectroscopy-based strategy to address the question of 
whether adipose IRF3 activity is elevated in obesity. 
 In this study we identified two important roles for IRF3 in the adipose tissue.  
However, it still remains a question whether some of the phenotypes we observed are 
entirely due to IRF3’s role in the adipocyte or if there were confounding effects from 
other cell types.  The lack of a floxed IRF3 mouse model limits our ability to completely 
work out IRF3’s role in metabolism.  A tissue specific knockout model would allow us to 
dissect the role of IRF3 in each metabolic tissue, especially its differential role in WAT 
and BAT.  To this end, we plan to create a floxed IRF3 mouse model as the next stage of 
this project. 
We are also interested in the pathways that lead to IRF3 activation in adipocytes.  
IRF3 activation is well studied in immune cells, where IRF3 acts downstream of TLR4.  
Activation of TLR4 after viral or bacterial infection results in activation of the kinases 
Tbk1 and Ikkε, which together phosphorylate and activate IRF3
91
.  Both TLR4 and Ikkε 
have been found to be expressed in adipocytes.  TLR4 has been shown to be a direct 
target of free fatty acids
80
.  Metabolic characterization of Tlr4
-/-
 mice and mice lacking 
TLR4 in hematopoietic cells show increased insulin sensitivity
80, 250
.  Ikkε is also linked to 
metabolism in that obesity increases liver and adipose Ikkε expression
95
.  Ikkε
-/-
 mice are 
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protected from diet induced obesity and insulin resistance.  Additionally, they exhibit 
increased food intake, body temperature, and energy expenditure
95
.  These data 
correlate with our observations in the Irf3-/- mice in vivo as well as in Irf3-/- adipocytes in 
vitro.  This suggests that IRF3 may act downstream of TLR4 and Ikkε in adipocytes.  We 
plan to begin by performing in vitro experiments in 3T3-L1 adipocytes to study if 
overexpression or knockdown of TLR4 or Ikkε results in similar effects as that of IRF3.  
Then use epistasis experiments to determine if knockdown of IRF3 in 3T3-L1 adipocytes 
abolishes the effects of TLR4 and Ikkε. 
 In the process of characterizing the Irf3-/- mouse, we found them to be resistant 
to HFD-induced liver steatosis.  This points to a potential role for IRF3 in liver 
metabolism.  Seo et al. recently found viperin, a viral response protein encoded by the 
Rsad2 gene, to have a role in inhibiting fatty acid oxidation
251
.  Interestingly, viperin 
expression was significantly up-regulated by IRF3 overexpression and down-regulated 
by IRF3 knockdown in our microarray in 3T3-L1 adipocytes.  Therefore we hypothesize a 
potential pathway where IRF3 acts through viperin to regulate fatty acid oxidation in the 
liver.  This will be one of our new directions in the study of IRF3 in metabolism. 
 In conclusion we found IRF3 to be a regulator of adipose metabolism, specifically 
suppressing adipocyte “browning” and insulin-stimulated glucose handling.  Although 
further studies are still needed to fully delineate IRF3’s role in metabolism, these results 
clearly indicate that IRF3 is a critical transcriptional regulator of the crosstalk between 
the immune and the metabolic systems. 
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